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Hemophilia B is the congenital bleeding disorder caused by deficiency in 
functional coagulation factor IX (FIX) and about 28,000 patients worldwide in 2012. And 
current treatment is restricted to protein-replacement therapy, which required FIX 
concentrates for patients’ life-time. Approximately 1 billion units FIX were consumed in 
2012. However, still about 70-80% patients, mostly in developing countries, received 
inadequate or no treatment because of the unavailable and/or unaffordable FIX 
concentrates. Considering safety reasons, e.g. transmission of blood-borne diseases, the 
recombinant human FIX (rFIX) is recommended other than the plasma-derived FIX. 
However, only one rFIX is currently available on the market.  The complexity of the FIX 
protein and its post-translational modifications (PTMs) cause the limit quantity and 
unaffordable high price of the recombinant human FIX. We previously reported 
successfully expressing recombinant human FIX in the milk by mammary gland of 
transgenic pig (tg-FIX) and established a lab-scale purification protocol to achieve active 
tg-FIX. The expression of tg-FIX level was about 2-3 g/L and with 10-20% specific 
activity. The final purified high acidic tg-FIX had the specific activity closed to the 
normal human plasma derived FIX. In this study, efforts were aim to further increase the 
yield of the active tg-FIX from the transgenic pig.  First, we investigated 
degradation/activation of the tg-FIX in the milk by predominant milk-borne protease, 
plasmin. This provided us the data in decreasing the degradation and activation of final 
products. Then, to process the excessive non-active pro-peptide attached tg-FIX, we bio-
engineered the mammary gland by introducing truncated human furin gene.  The co-
expressed recombinant furin cleaved pro-peptide of tg-FIX both in mammary epithelium, 
it also secreted and cleaved the pro-peptide in milk. This bio-engineering has been proved 
not interfering the over-expression of the tg-FIX and its specific activity. Finally, to mass 
producing active tg-FIX, we established the large scale purification protocol. The purified 
active tg-FIX was achieved within four chromatography steps with full specific activity. 
Not like the previous one, the active tg-FIX was further enriched and the contaminant 
activated tg-FIX was totally eliminated. This study made progress in producing 
recombinant human FIX economically. 
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CHAPTER 1: INTRODUCTION 
 
BACKGROUND 
Coagulation factor IX and Coagulation Cascade 
Coagulation Factor IX (FIX) gene is located on the X-chromosome at q27. Gene is 
expressed in hepatocytes with a highly tissue-specific manner as a pre-pro form (Fig.1) 
(1,2). The primary structure of FIX protein consist 40 amino acids ɤ-carboxyglutamate 
(Gla) domain, two Epidermal Growth Factor (EGF) domains (a.a. 47-127), activation 
peptide (a.a. 146-180) and the catalytic domain (a.a. 181-415). The first two domains 
compose the light chain (Mr. ~20 kDa) and the catalytic domain composes the heavy 
chain (Mr. ~28 kDa), in which His-221, Asp-269 and Ser-365 compose the serine 
protease catalytic triad. The nascent FIX is proceeded by several post translational 
modifications (PTM)s (Fig. 1), including the removal signal peptide, vitamin-K 
dependent gamma-carboxylation of first 12 glutamic acid(3,4), pro-peptide removal(5,6), 
glycosylation(7-10), beta-hydroxylation of Asp-64(11), sulfation of Tyr-155(12) and 
phosphorylation of Ser-158(13-15).  
At the physiologic concentrations of Ca
2+
 (1.1 mM ) and Mg
2+
 (0.6 mM), the core Gla 
domain  of  Vitamin K dependent (VKD) coagulation proteins like Protein C, Factor VII, 
Factor X and prothrombin have 4 Ca
2+ 
and 2 Mg
2+
 specific sites and also 1 binding site 
that can accommodate either divalent cation. The FIX has 2 additional Gla than other 
VKD factors and one more Mg
2+
 specific sites. Binding of above cations to the Gla 
domain is required for its conformational rearrangement from a disordered form to an 
ordered and organized form(16,17); This conformational rearrangement is essential for 
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factor IX to bind to negatively charged phospholipid vesicles provided in vivo by 
activated platelets resulting in its local ionization and augmentation of activation(18). Gla 
domain also interacts with the C-terminal domain of TF in the TF/FVIIa complex during 
the FIX activiation (19). In addition, the it is essential for FX activation by binding of 
FVIIIa, co-factor of tenase complex(20).   
 
Fig.1. The Primary Structure of Nascent FIX, Zymogen, Activated FIX and their 
PTMs. S: signal Peptide; P: pro-peptide; Gla: ɤ-carboxylglutamate domain; EGF: 
epithelium growth factor domain; AP: activation peptide; : signal peptide cleavage site; 
: pro-peptide cleavage site; : ɤ-carboxylglutamates; : O-link glycans; : N-link 
glycans; : disulfide bonds; : activation cleavage sites.  
The mature FIX secrets and circulates as a 55-57kDa zymogen form in the blood at a 
physiological concentration of 5 μg/ml (21). When tissue damage occurs, the blood 
coagulation cascade is initiated when the tissue factor (TF) comes in contact with 
activated factor VII (FVIIa). The TF-FVIIa complex initiates the coagulation cascade and 
finally forms the insoluble clot of activated platelets and fibrin polymers. Thrombin 
generated in the extrinsic pathway also activates the intrinsic pathway of blood 
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coagulation (Fig. 2) (22). Bauer, et. al. reported that FIXa generated in vivo mainly from 
the activity of the TF-FVIIa rather than the intrinsic pathway(23). 
 
Fig. 2. The Coagulation Cascade. (Modified from Davie, E.W., et. al. The coagulation 
cascade: initiation, maintenance, and regulation. Biochemistry 30, 10363-70 (1991). 
Role of Pro-peptide in γ-carboxylation and Pro-peptide Processing 
Furie et. al. reported the deletion of the pro-peptide (residues -18 to -1) inhibiting vitamin 
K dependent carboxylation(24). Study of in vitro carboxylation indicated the carboxylase 
recognition sites was the pro-peptide (25,26). And in the study of pro-peptides between 
Vitamin K dependent proteins, the amino acids sequence showed highly homological at 
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Phe
-16
 and Ala
-10
. Both mutation in pro-peptide, Phe
-16
 to Ala and Ala
-10
 to Glu 
completely inhibited the carboxylation (27,28). It is indicated that the role of pro-peptide 
in carboxylation, and the order in PTMs, the removal of pro-peptide should follow the 
gamma-carboxylation. 
In addition, homology is shown in basic amino acids at residues -4, -2 and -1(29,30). 
Both FIX Cambridge (Arg
-1
 to Ser) and FIX San Dimas (Arg
-4
 to Glu) are partially 
carboxylated and having pro-peptide attached hemophilia FIXs (31,32). In studies of 
other hemophilia FIXs with the mutation in Arg
-4
 to Gln (FIX Seattle C), Leu (FIX 
Bendorf) or Trp (FIX Boxtel), although mutations do not affect gamma-carboxylation, 
the defective propeptide cleavage results in destabilizing the calcium-induced Gla domain 
conformation change and no pro-coagulation activity of pro-peptide attached FIX (33).  
Furin or paired basic amino acid cleaving enzyme (PACE), a Ca
2+
 dependent serine 
protease of the PC family, cleaves pro-peptides at dibasic sites with consensus sequence 
Arg-X-Lys/Arg-Arg (RXK/RR)(34). Furin undergoes an auto-activation, the 83-residue 
N-terminal propeptide is autoproteolytically excised in the endoplasmic reticulum (ER) at 
the consensus furin site, -Arg
104
-Thr-Lys-Arg
107
-. Then, the propeptide attached furin 
transport to the acidified TGN/endosomal compartments, furin cleaves the bound 
propeptide at P1/P6 Arg site (-Arg
70
-Gly-Val-Thr-Lys-Arg
75
-) resulting in propeptide 
dissociation and enzyme activation(35). The mature furin is localized primarily to the 
trans-Golgi network (TGN)(36-39), and also traffics between TGN and cell 
surface(40,41). The previous study also indicated that ER retention of furin blocked it 
activation resulting in no bioactivity. On the other hand, the vitamin K-dependent 
carboxylase is an integral membrane protein associated with endoplasmic reticulum(24). 
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The order in location of carboxylase (ER) and furin (TGN) in vivo assure the pro-peptide 
removal after the carboxylation formed. 
Hemophilia B and Protein Replacement Treatments 
Hemophilia B is the congenital bleeding disorders and is caused by deficiency in 
functional coagulation factor IX (FIX). Various mutations in FIX gene can impair the 
pro-coagulation activity of the FIX protein, resulting in bleeding-disorder(42). Since this 
an X-linked recessive chromosomal disorder, almost all Hemophilia B patients are male, 
25,850 (92%) patients were male; only 719 (3%) patients were female (43). In absence or 
abnormal level of functional FIX, both the extrinsic and intrinsic coagulation pathway 
cannot be accomplished, patients experience frequent and recurrent bleeding episodes. 
Soft tissue hemorrhages and intracranial bleeding, potential to cause long-lasting damage 
to internal organs and can be life-threatening in some instances(44). Recurrent bleeding 
episodes are also associated with a range of longer-term clinical consequences, including 
musculoskeletal problems, which have the potential to restrict functional impairment in 
later life (45). The degree of impact associated with hemophilia is determined by the 
severity of the condition (46,47). Approximately 60–70% of hemophilia B patients have a 
moderate (defined as clotting factor concentration 0.05–0.40 IU/ml, experience prolonged 
bleeding responses to relatively minor trauma) or severe (<0.01 IU/ml, experience 
frequent spontaneous bleeds) form of the condition(48-50). Current treatment of 
hemophilia B is restricted to protein-replacement therapy, which centers on two distinct 
approaches: on-demand treatment and prophylaxis. The on-demand treatment offers 
short-term and immediate compensation of FIX to stop further hemorrhaging and 
minimize the impact of a bleeding episode. Conversely, prophylaxis focus upon 
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maintaining acceptable levels of baseline FIX, which decrease the frequency of acute 
hemorrhage and life-threatening bleeding episodes and is associated with better long-term 
outcomes (e.g. preventing joint damage and arthropathy)(51-53). In 2012, approximately 
250 million units of FIX concentrate was consumed in U.S., and about 1 billion units 
worldwide(43). Currently, there are 15 FIX concentrates on the market (Table 1). 14 of 
them are plasma derived (pd-) FIX, although the purification protocols was improved in 
virus removal over the last 20 years, there are still some concerns regarding prions and 
non-capsulated viruses (54,55). Only one is recombinant (r-) human FIX (BeneFIX), 
which was introduced by 1988 to the market(56), and it has been proven to be safe and 
effective with low incidence of serious adverse effects(57).  
Brand Name Company Source Fractionation Viral Inactivation 
Specific 
Activity 
(IU/mg) 
Aimafix® Kedrion Plasma 
Anion exchange, 
DEAESephadex®/Sepharose®, 
Heparin-affinity chromatography 
TNBP/polysorbate 80;  
dry heat, 100°C for 30 min; 
nanofiltration, 35 + 15 nm 
>100 
AlphaNine® 
SD 
Grifols Plasma 
Dual polysaccharide ligand 
affinity chromatography 
S/D: TNBP/polysorbate 80; 
nanofiltration 
210 
Berinin® P CSL Behring Plasma 
DEAE Sephadex, 
Heparin-affinity chromatography 
Pasteurization at 60°C  
for10 hours 
146 
Betafact® LFB Plasma 
Ion exchange, 
affinity chromatography 
TNBP/polysorbate 80; 
nanofiltration, 15 nm 
110 
Factor IX 
Grifols® 
Grifols Plasma 
Precipitation,  
Multiple chromatography 
S/D;  
nanofiltration, 15 nm 
>150 
Haemonine® Biotest Plasma 
Anion exchange,  
Immunoaffinity, 
Hydrophobic–interaction 
chromatography 
TNBP/polysorbate 80; 
nanofiltration, 15 nm 
>70 
Hemo-B-
RAAS 
Shanghai 
RAAS 
Plasma 
Ion exchange,  
Affinity chromatography 
S/D; dry heat; 
nanofiltration 
>50 
Immunine® 
Baxter 
BioScience 
Plasma 
Ion exchange,  
Hydrophobic-interaction 
chromatography 
Polysorbate 80;  
vapor heating,60°C for 10 
hours; 190 mbar, then 80°C 
for 1 hour, 375 mbar 
∼100 
Mononine® CSL Behring Plasma Immunoaffinity chromatography 
Sodium thiocyanate; 
ultrafiltration 
>190 
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Brand Name Company Source Fractionation Viral Inactivation 
Specific 
Activity 
(IU/mg) 
Nanotiv® Octapharma Plasma 
Ion exchange, 
Affinitychromatography 
TNBP/Triton® × 100; 
nanofiltration 
>150 
Nonafact® Sanquin Plasma 
Immunoaffinity,  
Hydrophobic-interaction 
chromatography 
TNBP/polysorbate 80; 
nanofiltration, 15 nm 
≥200 
Octanine F® Octapharma Plasma 
Ion exchange,  
Affinity chromatography 
TNBP/polysorbate 80; 
nanofiltration 
>120 
Replenine®-
VF 
Bio products 
laboratory 
Plasma Metal chelate chromatography S/D; nanofiltration, 15 nm 200 
TBSF FIX 
CSL 
biotherapies 
Plasma 
Ion exchange, 
Heparin-affinity chromatography 
TNBP/polysorbate 80; 
nanofiltration 
>50 
BeneFIX® Pfizer 
Recom
binant 
Anion chromatography Nanofiltration ≥200 
Table 1. Factor IX Concentrates on Market (Modified from Franchini, M., et. al. 
Treatment of hemophilia B: focus on recombinant factor IX. Biologics 7, 33-8 (2013)). 
Abbreviations: DEAE, diethylaminoethanol; S/D, solvent–detergent; TNBP, tri-n-butyl 
phosphate. 
 
Although the in vivo activity recovery of r-FIX lower than the pd-FIX results in 1.5 to 2-
fold increasing in r-FIX dosing(58,59), considering bio-safety reasons, the application of 
r-FIX products is widely recommended(60) In United States, 99% of consumed FIX 
concentrate was recombinant, while only 59% worldwide in 2012(43). The FIX 
concentrates account for up to 98% of the total cost of hemophilia care(61). Mean annual 
coagulation factor costs for on-demand treatment of haemophilia (A and B) ranging from 
€ 24,771 ($34,184) in the United Kingdom to €92,918 ($128,227) in Germany, ranging 
from €112,727 ($155,563) in Netherlands to €182,075 ($251,264) in Germany for 
prophylaxis(62). Approximately 80% patients, mostly in the developing countries, 
received inadequate or no treatment because of the limited supplies and high costs of 
either r- or pathogen screened, pd-FIX concentrates(63,64).  
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Recombinant Therapeutics Production and Transgenic Livestock  
The first therapeutic protein was the porcine insulin in 1920s, and recombinant human 
insulin prepared in bacteria was introduced in the market by early 1980s. By using the 
recombinant therapeutics, no more contamination of blood-borne pathogen needs to be 
worried about. Because of the complexity of the human protein and their in vivo post-
translational modifications (PTMs), the bacteria had its limitation in producing 
recombinant proteins. Then, yeast, insect cells, mammalian cells, transgenic plants and 
animals were developed in producing complex therapeutics, which could not be produced 
correctly by bacteria. The Chinese Hamster Ovary (CHO) cells were widely used in 
current industrial scale manufacturing. All these therapeutic bioreactor systems has their 
advantages and limitations (Table 2) 
Points to consider 
Production systems 
Bacteria Yeast 
Insect 
cells 
Animal cells 
(CHO cells) 
Transgenic 
plasnts 
Transgenic 
animals 
Practical production 
level 
++ (+) ++ (+) + + ++ ++++ 
Investment cost +++++ +++++ ++ + ++++ +++ 
Production cost +++++ +++++ ++ ++ +++++ ++++ 
Line stability +++++ +++++ ++++ +++ +++++ +++++ 
Scaling up +++++ +++++ ++ + +++++ ++++ 
Collection +++++ +++++ +++++ +++++ +++++ ++++ 
Post-translational 
modifications 
+ ++ +++ ++++ +++ ++++ 
Stability of product +++++ +++++ +++ +++ ++++ ++++ 
Purification +++ +++ +++ ++++ +++ +++ 
Table 2. Comparison of the different systems to produce recombinant pharmaceutical 
proteins. (Modified from Houdebine, L. M. Production of pharmaceutical proteins by 
transgenic animals. 2009.) 
Transgenic Livestock in Producing Recombiant Therapeutics 
In 1985, Hammer and colleagues established the first transgenic livestock animals(65). 
Since then, more and more pharmaceutical recombinant proteins were produced by using 
the transgenic animals (66-69). Mammary gland is currently the best available bioreactor 
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among all tissues in transgenic animals (66,68). The cell density of the gland is about 10
9
 
cell mL
-1
, which could be 2-3 orders of magnitude greater than density of mammalian 
cells culture (64); the milk production, pig as example is about 200-400 liters per 
lactation with 1-2 lactations per year; and more important, the mammary gland of 
transgenic animals could provide certain PTMs, like signal and pro-peptide removal, 
sulphation, glycosylation, carboxylation, which highly relate to the activity and recovery 
in vivo, to the recombinant proteins. And the transgenic pig was successfully in 
producing recombinant human PC(70,71), fibrinogen(72), FVIII(73) and FIX(74) in the 
milk.  
The most successful example, ATryn, human antithrombin , is made from the milk of 
transgenic goats and approved by FDA in 2009 or treatment of patients with hereditary 
antithrombin deficiency(75). Only one transgenic goat produced same amount of 
antithrombin in a year as 90,000 blood donations (76). The cost and easy scaling up of 
therapeutics production is also the advantage of the transgenic livestock bioreactor. A 
previous study suggested that building a large-scale (10,000 liter bioreactor) 
manufacturing facility for mammalian cells takes 3–5 years and costs US$ 250–500 
million, whereas a transgenic farm with a single purification facility should not cost more 
than US$80 million and would most likely cost less (66). So that, using the mammary 
gland of transgenic livestock as the bioreactor to express recombinant human FIX (tg-
FIX) could be a promising source to produce FIX concentrates in a safe and more 
economical way. However, because of the complexity of the PTMs of human FIX, no all 
transgenic livestock are suitable for manufacturing this recombinant therapeutics. No 
active FIX had been detected in the transgenic sheep milk(77). Zhang et al reported 
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that >90% recombinant protein in milk appeared to be a gamma-glycosylated and 
biologically active but the expression level was only 13.7 ng/mL(78). 
Current Progress and Specific Aims 
Our lab has generated transgenic pigs that express high level (2-3 g/l) transgenic FIX (tg-
FIX) in the milk, and also developed the protocol for purifying active tg-FIX by using the 
combination of heparin-affinity chromatography (whole tg-FIX population) and anion 
exchange (Mini Q) chromatography (high acidic/carboxylated tg-FIX subpopulation); the 
final purified tg-FIX had the specific activity at 197 U/mg(74). This tg-FIX was 
characterized in extent of ɤ-carboxylglutamate and N-glycosylation. Not like the plasma-
derived human FIX, the tg-FIX has different extent of carboxylation subpopulations. At 
tg-FIX expression level was at 200 µg/L milk, it was highly carboxylated (≥10) (79). 
However, when the expression level increased about 1,000-fold (2 mg/ml), only 10-20% 
was highly carboxylated (74), this indicated the enzymatic PTMs were rate limited and 
block the yield of the active tg-FIX production. Van Cott et. al. reported the majority of 
the N-glycans of this tg-FIX were complex, bi-antennary, while pd-FIX N-glycans were 
highly branched (tri- and tetra-antennary), and highly sialylated. No detectable Neu5Gc 
nor Galα(1,3)Gal in tg-FIX, which is strongly antigenic in human(80). We also noticed, 
at this high tg-FIX expression level, approximately 10-30% of total tg-FIX population is 
pro-tgFIX (pro-peptide attached tg-FIX) that has no pro-coagulation activity. In addition, 
we noticed certain amount of degraded/activated tg-FIX in the high acidic tg-FIX 
subpopulation.  
In this study, we were working on the following specific aims: 
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Specific Aim#1: Characterize the tg-FIX and its degraded species in purified high acidic 
tg-FIX subpopulation. And investigate the predominant milk-borne protease, plasmin, in 
degrading the tg-FIX and the extent of the Gla in protecting FIX being cleaved. 
Specific Aim#2: Bioengineer pig mammary gland by introducing truncated human furin 
gene co-expressing with tg-FIX. Characterize the recombinant truncated human furin (r-
furin) in processing the excessive pro-peptide and convert non-active tg-proFIX to active 
tg-FIX both in vivo and in vitro.  
Specific Aim#3: Establish scaled-up purification protocol, using the more efficient, 
immunoaffinity chromatography FIX select column to capture whole tg-FIX population 
from transgenic milk; then enrich high acidic tg-FIX by anion exchange chromatography; 
finally isolate the active tg-FIX subpopulation by using HPLC-SEC.  
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ABSTRACT 
The milk-borne plasmin, identical to the one in the plasma, is the predominant protease in 
the milk. Producing of recombinant human coagulation factor IX (tg-rhFIX) in milk by 
mammary gland of transgenic pig could also be proteolyzed by the plasmin as native milk 
borne protein. The previous study of proteolysis of plasma-derived (pd-) human FIX by 
pd-plasmin showed the yield of the activated and/or degraded tg-rhFIX. Tg-rhFIX 
expressed in the milk frequently has subpopulations with less than a full complement (12) 
of ɤ-carboxylated glutamic acid (Gla), which alters the divalent metal-dependant 
conformation of the Gla domain. We noticed the cleavage of tg-rhFIX was altered by the 
extent of ɤ-carboxylated in tg-rhFIX in the presence of Ca2+. The low Gla content 
(≤10/12) tg-rhFIX subpopulations were frequently cleaved in the light chain at Gln44 but 
not in tg-rhFIX with high Gla content (≥10/12).  This cleavage was also seen in the tg-
rhFIX with high Gla content (≥10/12) in a chelated environment. The conformation 
rearrangement of high extent Gla induced by Ca2+ prevented the Gla domain being 
cleaved by plasmin.  
Key words: factor IX, ɤ-carboxyglutamic acid, plasmin, proteolysis 
 
INTRODUCTION 
Factor IX (FIX) is a member of the vitamin K dependent family of proteins and a 56 kDa 
zymogen form of the serine protease activated FIX (FIXa) that contains several divalent 
metal binding domains including an amino-terminal region consisting of 12 γ-
carboxyglutamic acid residues (Gla). At the physiologic concentrations of 1.1 mM Ca
2+
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and 0.6 mM Mg
2+
, the core Gla domain  of  Vitamin K dependent (VKD) coagulation 
proteins like Protein C, Factor VII, Factor X and prothrombin have 4 Ca
2+ 
and 2 Mg
2+
 
specific sites and also 1 binding site that can accommodate either divalent cation. The 
FIX has 2 additional Gla than other VKD factors and has one more Mg
2+
 specific sites. 
Recombinant versions of FIX (rh-FIX) frequently contain subpopulations with less than 
12 Gla residues (1,2).  The difference in extent of ɤ-carboxylation causes subpopulations 
with a range of biological activity. The metal-dependent conformation of the Gla domain 
is essential for factor IX to bind to negatively charged phospholipid vesicles provided in 
vivo by activated platelets resulting in its local ionization and augmentation of activation 
(3) and interacts with the C-terminal domain of TF in the TF/FVIIa complex during the 
FIX activiation (4), in addition, is essential for FX activation by binding of FVIIIa, co-
factor of tenase complex(5). Thus, the Gla domain plays a large role in the nature of 
proteolysis that occurs with zymogen FIX and other VKD proteins by serine proteases 
that regulate coagulation. 
Plasmin is the major source of protease activity in milk (6). Furthermore, plasmin and 
plasminogen in milk are essentially identical to those found in blood having similar heat 
and pH stabilities, pH optima for casein hydrolysis, inhibitor susceptibility (7-9)  and 
primary structure (10).  Human plasma derived plasmin has been shown to proteolyze 
FIX into four products having apparent molecular weights of 45 kDa, 30 kDa, 20 kDa 
and 14 kDa when analyzed by reduced SDS-PAGE and two products at 52 kDa and 14 
kDa under non-reducing conditions (11). Sequence analysis demonstrated that cleavage 
occurred after Lys
43
, Arg
145
, Arg
180
, Lys
316
 and Arg
318
.  The conformational specificity of 
plasmin on FIX structure was indicated by the proteolysis at only 5 of the possible 43 
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plasmin sites within pd-FIX (12). The divalent metal induced conformational dependence 
of proteolysis (13) by plasmin has been shown in fully carboxylated pd-FIX but not 
partially carboxylated, biologically active rFIX. Plasmin proteolysis of FIX during 
circulation is normally inhibited by α2-antiplasmin inhibitor (14). 
We previously reported producing recombinant human FIX (tg-rhFIX) in the mammary 
gland of transgenic pig, this expression level was about 2-3 g/L in the milk (15). This 
contrasts previous studies on the expression of tg-rhFIX in the milk of sheep which was 
largely inactive and had low levels of Gla content and appeared proteolyzed (16).  Like 
that of recombinant FIX made by CHO cells (CHO-rhFIX), which contains different 
extent of Gla subpopulations (2), we fractionated tg-rhFIX into active and inactive 
subpopulations based upon differences in Gla content. As human and porcine 
plasminogen closely related (17,18), we here study the proteolysis of tg-rhFIX, 
therapeutic grade CHO-rhFIX and fully carboxylated pd-hFIX by human plasma derived 
plasmin. We also compare this proteolysis to that found in tg-rhFIX made in milk. In 
contrast to previous proteolysis studies of pd-FIX, we report on the differential 
proteolysis by plasmin to tg-rhFIX with different extent of Gla.  
 
MATERIALS AND METHODS 
All buffer components were purchased from VWR International LLC (Radnor, PA) or 
Thermo Fisher scientific (Waltham, MA) or Sigma (St. Louis, MO) unless otherwise 
stated. Reference pd-FIX (Mononine, CSL Behring, USA) and CHO-rhFIX (BeneFIX, 
Pfizer Limited USA) were kind gifts from James Brown (Lincoln, NE).  These stocks of 
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were expired for clinical use but exhibited full procoagulant activity by one stage clotting 
assay.   
Purifying High Acidic Tg-FIX from Transgenic Pig Milk  
The purification procedures were adapted from previous described (15). The collected 
milk was adjusted to 100 mM EDTA to dissolve the casein micelle, which recover more 
tg-rhFIX, and stored at -80
o
C. The milk was thawed and then centrifuged (12,800 X
 
g for 
20 minutes) to remove the insoluble fat contained in an upper layer and solid particulates 
that were contained in the lower layer. The decanted middle layer or clarified milk was 
mixed with 4 parts 20 mM Tris, 50 mM NaCl, pH 7.4. The diluted, clarified milk was 
then loaded onto a Heparin sepharose 6 Fast Flow (GE Healthcare Bio-Sciences AB, 
Sweden) column, 10 mm I.D. X 150 mm L (11.8 mL), with the flow rate at 150 ml/hr. 
Then the column was washed with 20 mM Tris, 200 mM NaCl, pH 7.4 to remove caseins 
then with 20 mM Tris, 500 mM NaCl, pH 7.4 to elute FIX. The eluate (EL) was 
exchanged into the equilibrium buffer (20mM potassium phosphate, pH 7.2) and loaded 
on the Ceramic Hydroxyapatite (CHT) (Macro-Prep Ceramic Hydroxyapatite Type II, 40 
µm, Bio-Rad Laboratories, Inc., Hercules, CA) column, 10 mm I.D. X 150 mm L (11.8 
mL), with the flow rate at 150 ml/hr. The tg-FIX was eluted with a linear gradient from 
20 mM to 400 mM Sodium phosphate, pH 7.2. Latter portion (about 15%) of CHT eluate 
(EL) was collected. The purifications were performed on a BioCAD Vision 
chromatography station (Applied Biosystems, Grand Island, NY). In order to minimize 
degradation, purification processes were performed at 4°C. 
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Analyzing High Acidic FIX population by High Performance/Pressure Liquid 
Chromatography-Size Exclusion Chromatography (HPLC-SEC) 
The high acidic tg-rhFIX was exchanged into SEC running buffer (20 mM Tris, 200 mM 
NaCl, 10 mM CaCl2, pH 7.4) by using the Minimate tangential flow filtration systems 
with 10 kDa molecular weight cut off (MWCO) membrane (Pall Corporation,  Port 
Washington, NY) or Amicon tube (10 kDa MWCO) (EMD Millipore, Billerica, MA). 
Tg-FIX sample was loaded on a TSK gel G3000SWXL, 7.8 mm ID x 30 cm, 5 µm 
(particle size), equipped with a guard column, 6 mm ID x 4 cm, 7 µm (particle size), 
(Tosoh Bioscience, LLC). Columns was equilibrated and run with 20 mM Tris base, 200 
mM NaCl, 10 mM CaCl2, pH 7.0. The flow rate was 0.5 ml per min and duration of the 
run was 45 min with all major peaks eluting before 35 min. The fractions of each peak 
were pooled together for further analysis. 
Sodium Dodecylsulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)   
SDS-PAGE was performed using precast 12% Bis-Tris Novex acrylamide gels. The gels, 
4x sample buffer, 10x reducing agent, molecular weight marker and 20x running buffer 
were all from Invitrogen (Carlsbad, CA). Samples were incubated with reducing or non-
reducing sample buffer at 70 ℃for 10 minutes prior to electrophoresis at 200 V using the 
Invitrogen XCell Surelock mini cell. Gels were stained with Colloidal Blue (Invitrogen).   
Detecting Pig Plasmin in Transgenic Milk by Western Blot  
Both human plasma derived (pd-) plasmin and plasminogen were purchased from 
Haematologic Technologies Inc. (Essex Junction, VT). And all milk samples were 
skimmed and loaded on the SDS-PAGE as described and then gels were electro-blotted 
onto poly vinylidene fluoride (PVDF) membranes using a BioRad  Transblot SemiDry 
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Transfer Cell (Richmond, CA) for 30 min at 25 volts.  For detecting both plasmin and 
plasminogen, the primary antibody, Chicken IgY anti-pig plasminogen (MBS560144, 
MyBioSource, Inc. San Diego, CA) and secondary antibody, Goat anti-Chicken IgY-HRP 
(SA114013, Thermo Scientific, Rockford, IL), were used .The chromogenic DAB 
substrate (Thermo, Rockford, IL) was used in color developing. 
NH2-terminal Sequencing of the Plasmin Cleavage Products of FIX 
Amino acid sequencing was performed at the University of Nebraska Medical Center, 
Protein Structure Core Facility. Protein samples were subjected to SDS-PAGE and 
transferred to PVDF membranes as described above. The membrane was stained with 
Colloidal Blue and bands excised and subjected to Edman degradation using Applied 
Biosystems Procise protein sequencer, a Hitachi 8800 Amino Acid Analyzer and a 
Michrom MAGIC HPLC equipped with a Diode Array Detector. 
Quantitation of Total Factor IX Activity 
Total FIX activity was determined using the activated partial thromboplastin time (aPTT) 
assay (19). Briefly, 50 µl each of PTT Automate 5 reagent (Diagnostica Stago, Inc., 
Parsippany, NJ), factor IX deficient plasma (George King Bio-Medical, Overland Park, 
Kansas, USA), and a sample of interest were added to a cuvette and incubated at 37 °C 
for 3 min. 50 µL of 25 mM CaCl2 (Sigma) was then added and the clotting time was 
measured using the STart Hemostasis Analyzer (Diagnostica Stago, Inc., Parsippany, NJ). 
The normal human plasma (Diagnostica Stago, Inc., Parsippany, NJ) was used as the 
standard, assigning 1 unit of FIX clotting activity per milliliter of plasma. The 
concentration of purified tg-rhFIX was determined by measuring the optical density at 
280 nm in a 1 cm quartz cuvette and using an extinction coefficient, ε1% =13.4.  
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Mass Spectrometry of Tg-rhFIX to Detect Gla Content 
All tg-rhFIX samples were activated with Factor XIa (Haemtech, Essex Junction, VT) in 
order to separate the light chain domain containing the Gla domain from the heavy chain 
domain  using a 1:100 (w:w) enzyme to substrate ratio in 5mM CaCl2, 1X TBS, pH 7.4 at 
37°C for 1.0 hour. After activation, the samples were quenched with 1.2 moles of EDTA 
per mole of calcium and stored at -80
o
C until further analysis. LC-ESI-TOF-MS analysis 
was performed on an Agilent 1200 capLC system with an Agilent 6210 ESI-TOF MS.  
Solvent A was 0.1% formic acid (Fluka) (v/v) in deionized water.  Solvent B was 0.1% 
formic acid (v/v) in acetonitrile (Burdick and Jackson).  The column was an Agilent 
300SB-C8 Poroshell column:  7.5 cm L x 0.5 mm ID, 5 micron particle size.  The 
samples were diluted in Solvent A in the HPLC vial and loaded in the autosampler.  
Approximately 35 pmol of sample was injected on the column in a 40 microliter injection 
volume.  The column was pre-equilibrated with 5%B; the flow rate was 20 
microliters/minute; the column oven was set at 37
o
C; the autosampler was set at 10
o
C.  
After injection, the column was washed for 5 minutes with 5%B, then a linear gradient up 
to 20%B over 10 minutes, followed by a linear gradient up to 55%B over 70 minutes.  
The column was then cleaned by ramping up to 95%B for 5 minutes and then a series of 
three cycles of 10%B to 70% B, and then the column was re-equilibrated for >10 CV 
with 0%B for the next injection.  A blank injection was performed in between each 
sample.  MS data were acquired with MassHunter in positive mode with the following 
parameters:  4000 V source voltage, 325
o
C nebulizing gas temperature, 7 L/min gas flow 
rate, internal reference mass of 922.01 m/z.  MS data were analyzed using Agilent’s 
Qualitative Analysis (version B.01.03).   
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Activating FIX to Activated FIX by FXIa 
CHO-rhFIX (BeneFIX, Pfizer Limited USA) and tg-rhFIX were activated to their 
activated forms by plasma derived human FXIa (Haematologic Technologies, Inc., 
Vermont, USA). The mass ratio of FIX to FXIa is 100:1 (w:w), and both were incubated 
in TBS (20 mM Tris, 0.15 M NaCl) pH 7.4 with 5 mM CaCl2 at 37°C for 2 hours. The 
reaction samples were exchanged into SEC running buffer and loaded on the HPLC-SEC 
as above. The fractions of FIXa was collected and pooled.  
Plasmin Digestion of FIX and Activated FIX 
FIX samples, including pd-FIX (Mononine, CSL Behring, USA), CHO-rhFIX (BeneFIX, 
Pfizer Limited USA) and high/low Gla tg-rhFIX, and activated FIX samples, including 
pd-FIXa (Haematologic Technologies, Inc., Vermont, USA), CHO-rhFIXa and tg-rhFIXa, 
were used in the assay. FIX and FIXa samples were incubated with plasma derived 
human plasmin (Haematologic Technologies, Inc., Vermont, USA) at 37°C using a 1:100 
(w:w) enzyme to substrate ratio in TBS (20 mM Tris, 0.15 M NaCl, pH 7.4) in the 
presence of 5 mM CaCl2 or 10 mM EDTA. Aliquots were took out at time = 0, 10, 20, 40, 
60, and 120 minutes and quenched with SDS sample loading buffer with reducing buffer 
(Invitrogen, Carlsbad, CA, USA), then analyzed by reduced and non-reduced SDS-PAGE. 
In addition, a negative control digest was analyzed with each sample by replacing the 
enzyme with water.  
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RESULTS AND DISCUSSION 
Detecting Porcine Plasmin in Transgenic Milk 
Transgenic milk samples, K75, K101, R175&179, R180 and R1014 lactation pools, were 
diluted and skimmed then loaded on the SDS-PAGE with the positive controls, human 
plasma derived (pd-) plasmin (83 kDa) and plasminogen (88 kDa). The antibody probed 
the plasmin as well. The ~ 83 kDa bands, shown in all transgenic milk samples, were 
porcine plasmin involving in proteolysis of tg-FIX in the transgenic milk.  The amount of 
plasmin is about 2 µg (compared to the pd-plasmin) in 10 µL diluted milk sample, which 
has about 10 µg tg-FIX (Fig 1).   
 
Figure 1. Non-reduced Western blot detecting porcine plasmin in the transgenic 
milk sample. Lane 1, human plasmin (83 kDa), 1 µg; lane 2, human plasminogen (88 
kDa), 1 µg; lane 3-7, transgenic milk K75, K101, R175&179, R180 and R1014 lactation 
pool, diluted 1:1 (v/v) and skimmed, 10 µL. 
 
State of Degradation of Biologically Active Tg-rhFIX Pool Isolated from Milk 
We previously reported that only 10-20% of the total tg-rhFIX in the milk has FIX 
specific activivity due to rate limitations in γ-carboxylation of the Gla domain (15).  We 
quantitatively captured these biologically active subpopulations as a pool using a 
sequence of heparin affinity and Ceramic Hydroxyapatite (CHT) chromatography. The 
high acidic tg-rhFIX obtained from CHT column contained all of the specific activity 
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present in the clarified whey. Conversely, the low acidic tg-rhFIX contained no 
biologically active species.   
 
Figure 2. SDS PAGE of most acidic tg-rhFIX pool from CHT chromatography.  
Panel A. Non-reduced and Panel B. Reduced SDS-PAGE of FIX samples.  Lane 1. pd-
FIX reference; Lane 2. CHO-rhFIX reference; Lane 3. tg-rhFIX CHT most acidic pool. 
Each lane contains 7µg of protein sample. The tg-rhFIX was purified from pig K108 milk 
pool from lactation days 16-24. 
 
Figure 2A compares a non-reduced Commassie Blue stained SDS-PAGE gel profile of 
the biologically active tg-rhFIX pool from CHT to highly purified, therapeutic grades of 
pd-hFIX and CHO-rhFIX. On the non-reduced SDS-PAGE, the majority of the tg-rhFIX 
appeared as a single band corresponding to the co-migration of both single chain and 
disulfide bridge-linked, two-chain species. The most common minor band in all samples 
was the proteolysis product termed FIXɤ that results from a cleavage at Arg318 and 
release of an 8 kDa carboxy-terminal peptide from the FIX parent (12). FIXɤ and the 
released ɤ-peptide were present in all preparations. The MW of FIX and FIXɤ species 
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present in pd-FIX and CHO-rhFIX were similar due to similar glycoforms and other post-
tanslational modifications (2), but were about 2-3 kDa larger than the respective species 
found in tg-rhFIX. This might be due to the presence of quarternary and ternary N-linked 
glycoforms on the activation peptide of pd-FIX and CHO-rhFIX versus the smaller 
bianternary glycoforms observed in tg-rhFIX (20).  
Reduced SDS-PAGE reveals the spectrum of two chain proteolytic products that were 
present in all FIX preparations where at least five bands appear in both reference and tg-
rhFIX samples (Figure 2B). Other than the zymogen form of tg-FIX (MW 54 kDa), the 
predominant tg-rhFIX degraded species was FIXα, MW is about 40 to 42 kDa (Figure 2B 
Lane 3), which results from the cleavage at Arg
145 
and
 
release of the light chain (LC) 
from the heavy chain (HC) attaching activation peptide (AP) (FIXα-HC).  This 
intermediate of activated FIX (FIXa), which had additional cleavage at Arg
180
 and release 
of the AP, is still a biological active form of FIX if the light chain was properly 
carboxylated and the propeptide was removed (21). 
Proteolytic Cleavages Detected by NH2-terminal Sequencing 
Table 1 summarizes the amino-terminal sequence analysis of protein bands observed by 
reduced SDS-PAGE (Figure 2B) in pd-FIX, CHO-rhFIX and the biologically active pool 
(high acidic) tg-rhFIX obtained by CHT. These cleavages are consistent with those 
commonly attributable to that made by plasmin (12). The degraded species appearing 
within the therapeutic grade pd-FIX and CHO-rhFIX were detected at 56 kDa, 48 kDa, 
40 kDa, 30 kDa, 18 kDa, and 8 kDa with amino terminal sequences corresponding to FIX 
zymogen, FIXɤ, FIXα-HC, FIXαɤ-HC, LC and the ɤ-peptide.  The similar degraded 
species appeared in tg-rhFIX were 54 kDa, 46 kDa, 38-40 kDa, 30 kDa, 17-18 kDa and 8 
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kDa.  In contrast to the more highly fractionated, therapeutic grade pd-hFIX and CHO-
rhFIX preparations, only the tg-rhFIX pool contained the FIXαβ-HC, which is the 
activated FIX, also FIXa, that possessed a MW of about 28-29 kDa.   
Band #
1
 M. W. (kDa) 
N-terminal a.a. 
Sequence 
Predicted FIX 
Species 
FIX Sample 
1 56 YNSGK FIX Zymogen 
pd-FIX 
2 48 YNSGK FIXγ2 
3 40 AETVF FIXα-HC3 
4 30 AETVF FIXαγ-HC4 
5 18 YNSGK LC 
6 8 SALVL γ-peptide 
7 56 YNSGK FIX Zymogen 
CHO-rhFIX 
8 48 YNSGK FIXγ 
9 40 AEAVF FIXα-HC 
10 30 AETVF FIXαγ-HC 
11 18 YNSGK LC 
12 8 SALVL γ-peptide 
13 54 YNSGK FIX Zymogen 
tg-rhFIX 
CHT high acidic 
eluate 
14 46 YNSGK FIXγ 
15 38-40 AETVF FIXα-HC 
16 30 AETVF FIXαγ-HC 
17 28-29 VVGGE FIXαβ-HC5 
18 17-18 YNSGK LC 
19 8 SALVL γ-peptide 
Table 1. NH2-terminal amino acids (a. a.) sequence of all bands on reduced SDS-PAGE 
of FIX samples and predicted FIX species. 
1
The band number is according to the number 
shown on the reduced SDS PAGE of FIX samples (Figure 2B). 2The FIXγ is the FIX 
zymogen without the c-terminal γ-peptide 3The FIXα-HC is the FIX zymogen without the 
light chain (LC); it the heavy chain (HC) with activation peptide (AP) 
4The FIXαγ-HC is 
the FIXα-HC without the c-terminal γ-peptide 5The FIXαβ-HC is the heavy chain alone. 
The FIXαɤ-HC retained the activation peptide but had the ɤ-peptide removed and was 
therefore inactivated (12).  In contrast, pd-FIXa consists of a FIXαβ-HC having an intact 
protease domain where when paired with an intact light chain possesses a high specific 
activity of about 6000 U/mg (measured plasma derived human activated FIX). Zymogen 
forms of FIX typically has specific activity of about 150-200 U/mg. Thus, the high 
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specific activity of high acidic pool tg-rhFIX from CHT  is seen to be caused by the 
presence of FIXa. 
Separate Active Tg-rhFIX Zymogen from CHT Eluate by HPLC-SEC 
The high acidic tg-FIX was loaded on the HPLC-SEC in the presence of calcium ion. 
Three peaks of species with different biological activity were isolated (Figure 3A, Table 
2).  Pool 1 (Figure 3B, lane 2) exhibited both a low biological activity by coagulation 
assay and low extent of ɤ-carboxylation (Table 3).  Pool 2 (Figure 3B, lane 3) and Pool 3 
(Figure 3B, lane 4) showed both a high specific coagulation activity (Table 2) and high 
extent of ɤ-carboxylation (Table 3) that was closed to that obtained for pd-FIX and CHO-
rhFIX. Both SEC pool 1 and 2 contained primarily FIX and FIXα and very minor 
amounts of FIXαɤ but not activated FIX.  Fraction 3 showed the highest specific activity 
of any FIX preparation which correlated well with a high content of FIXa and the 
respective FIXαβ-HC and LC content identified by N-terminal sequencing. This 
confirmed the origin of the high overall activity seen in the starting CHT eluate. 
Samples  Retention Time (min) Specific activity (Units/mg1) 
CHT Eluate N/A 1681 ± 187 
SEC Pool 1 16.5-20 11 ± 1 
SEC Pool 2 20.5-22.5 155 ± 13 
SEC Pool 3 23-28 3203 ± 890 
Mononine N/A 181 ± 8 
BeneFIX N/A 178 ± 14 
Table 2. The tg-rhFIX CHT most acidic eluate SEC pools and their FIX specific activity. 
1
One International Unit is the amount of factor IX activity present in 1 mL of pooled, 
normal human plasma. The specific activity of plasma derived human FIX is greater than 
or equal to 200 IU per milligram of protein. 
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Figure 3.  Fractionation by HPLC-SEC of high acidic tg-rhFIX population. Panel A. 
HPLC-SEC profile of  most acidic tg-rhFIX pool. SEC Pool 1, 2, and 3 collected from 
HPLC-SEC are as indicated.  Panel B. Reduced SDS-PAGE of SEC pools. Lane 1. 
Starting tg-rhFIX CHT eluate pool used for SEC fractionation; Lane 2, SEC pool 1; Lane 
3, SEC pool 2; Lane 4, SEC pool 3. All samples loaded 2 ug. 
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Gla Extent pd-FIX CHO-rhFIX 
SEC Pool  
1 2 
≥ 10 100% 100% < 20% ≥ 80% 
< 10 0 0 ≥ 80% < 20% 
Table 3. Extent of γ-carboxyglutamic acid (Gla) of FIX samples. 
 
In Vitro Plasmin Digestion of FIX Zymogen 
Time course plasmin digests of pd-FIX (Fig. 4A), CHO-rhFIX (Fig. 4B) and HPLC-SEC 
pool 1 (low Gla content) and 2(high Gla content) of tg-rhFIX (Figures 4C and D) done 
with Ca
2+
 (lanes 2-6) or in a chelated environment (lanes 9-13) were evaluated by SDS-
PAGE.  In general, for all FIX species evaluated here, the pathway of proteolysis at α 
(Arg
145
) and ɤ (Arg318) sites by plasmin took place at a faster rate in the presence of 
calcium than in EDTA. The rate and pathway of proteolysis in the presence of Ca
2+
 for 
SEC pool 2 tg-rhFIX was similar to that of pd-FIX and CHO-rhFIX proceeding primarily 
to FIXαɤ-HC. This showed that the origin of FIXαɤ-HC in the high acidic tg-rhFIX was 
likely caused by endogenous porcine plasmin in the milk.  However, no evidence of the 
cleavage at Arg
180
 and production of FIXa by plasmin were observed. 
The proteolysis at α and ɤ sites in a chelated environment was also similar for pd-FIX, 
CHO-rhFIX, tg-rhFIX SEC pool 1 and 2 (Fig. 4C and D, lane 9-13).  In contrast to that in 
the presence of Ca
2+ 
(Fig. 4C and D, lane 1-6), the proteolysis of the most carboxylated 
FIX species in 10 mM EDTA all shifted to a pathway that generated a cleavage in the 
light chain at Lys
43
 and releasing the Gla domain.  While FIXα was still made, but at a 
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slower mode, same as the proteolysis at Arg
318
.  The proteolysis of LC at Lys
43
 in less 
carboxylated tg-rhFIX, SEC pool 1, behaved similarly in either a Ca
2+
 or chelated 
environment. However, the proteolysis of the Arg
180
 and Arg
318
 in less carboxylated tg-
rhFIX behaved same as the other three FIX samples in both environments. We show for 
the first time that a non-native conformation due to a low extent of ɤ-carboxylation 
results in a prominent presentation of Lys
43
 site in the light chain that results in cleavage 
after. Our findings with the highly carboxylated SEC pool 2 tg-rhFIX are consistent with 
the previous observations of (22).  
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Figure 4.  Reduced SDS-PAGE of time course plasmin digestion of FIX in Ca2+ and 
in chelated environments. Panel A. pd-FIX; Panel B. CHO-rhFIX; Panel C. SEC Pool 2 
tg-rhFIX; Panel D SEC Pool 1 tg-rhFIX. For all panels:  Lane 1-6. plasmin treated 
sample in 5 mM CaCl2 at  t = 0, 10, 20 40, 60, and 120 minutes, respectively;  lane 7, 
untreated sample at t = 120 minutes. Lane 8-13 plasmin treated sample in 10 mM EDTA 
at t = 0, 10, 20 40, 60, and 120 minutes, respectively; No plasmin added sample in 10 
mM EDTA at t = 120 minutes. All lanes have 3.75 µg of FIX sample loaded. NH2- 
amino terminal sequencing of each protein species as indicated.   
 
In Vitro Plasmin Digestion of Activated FIX 
We examined FIXa stability in the presence of plasmin. The pd-FIXa, and activated 
CHO-rhFIX and tg-rhFIX SEC pool 2 (activated by FXIa in vitro) all exhibited a similar 
resistance to proteolysis at Arg
318
 by plasmin in the presence of Ca
2+ 
(Figure 5).  
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Figure 5. Reduced SDS-PAGE of time course plasmin digestion in Ca2+ and in 
chelated environments of activated FIX. Panel A. pd-FIXa; Panel B. CHO-rhFIXa; 
Panel C. Fraction 2 tg-rhFIXa; For all panels:  Lane 1-6. plasmin treated sample in 5 mM 
CaCl2 at  t = 0, 10, 20 40, 60, and 120 minutes, respectively;  lane 7, untreated sample at 
t = 120 minutes. Lane 8-13 plasmin treated sample in 10 mM EDTA at t = 0, 10, 20 40, 
60, and 120 minutes respectively; Lane 9: no plasmin added sample in 10 mM EDTA at t 
= 120 minutes. All lanes have 3.75 µg of FIX sample loaded. NH2 -amino terminal 
sequencing of each protein species as indicated. 
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The proteolytic product was FIXɤ-HC.  In a chelated environment, all FIXa species were 
rapidly proteolyzed at Lys
43
. This pattern is opposite from the proteolysis of FIX 
zymogen, and the only difference between the substrates was the activation peptide.  
 
CONCLUSIONS  
Consistent with the previous findings for fully carboxylated pd-FIX, we observed that 
both highly carboxylated CHO-rhFIX and tg-rhFIX will undergo efficient plasmin 
cleavage at Arg
145
 in the presence of calcium to form FIXα then FIXαɤ. But we did not 
see the cleavage at Arg
180
 which form the activated FIX. Although formation of FIXa 
from tg-rhFIX zymogen in milk was not directly caused by plasmin, the formation of the 
intermediate of activated FIX promotes the formation of the final activated tg-FIX by 
other protease, e.g. trypsin, in the milk. The proteolysis at Lys
43
 in light chain of FIX was 
noticed in the chelated environment, it was also seen in the low γ-carboxylated tg-rhFIX 
even in the presence of Ca
2+
. This indicated the Ca
2+
 induced conformational change of 
the Gla domain prevented it being proteolyzed by the plasmin. In order to decrease or 
eliminate the proteolysis of plasmin, specific protease inhibitor, e.g. ε-aminocarporic acid, 
and EDTA are required.  
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ABSTRACT 
28,008 patients worldwide had been diagnosed hemophilia B, which was congenital 
deficiency in coagulation factor IX (F9), and  1,005,358,368 IU F9 concentrates was 
consumed to treat those patients in 2012 (1). However, still about 70-80% patients 
received inadequate or no treatment because of unavailable and/or unaffordable factor 
concentrates (2). It is desired to manufacture safe and more economical F9. The higher 
cell density of the mammary gland, large quantity of milk production, and human-like 
post-translational modifications have been demonstrated to make bioactive recombinant 
(r) F9 at higher levels in mammary gland of transgenic pig than is currently done by 
using CHO cells. Cleavage of pro-peptide of nascent rF9, rate limit enzymatic 
modification, cannot be fully achieved by endogenous porcine furin at the high rF9 
expression rate in transgenic mammary epithelium. Our data showed about 10-30% of 
whole rF9 population was inactive pro-peptide attached rF9 (pro-rF9). In this study, we 
constructed transgene with both the truncated human furin and F9 gene and generated the 
pig by somatic cell nuclear transfer (SCNT) technology. We demonstrate that 
recombinant (r) furin was co-expressed with rF9 more than 2000 U/ml milk, and it 
converted the inactive pro-rF9 into active rF9 both in vivo and in vitro. No evidence was 
shown the co-expressing rfurin interfered the over-express (≥ 2g/L milk) and ɤ-
carboxylation of rF9. 
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INTRODUCTION 
Hemophilia B is the congenital bleeding disorders and is caused by deficiency in 
functional coagulation factor IX (F9); by 2012, there were 28,008 patients worldwide 
(1,3). Prophylactic therapy, intravenous infusions of F9 per week, significantly reduces 
internal bleeding episodes (ie., into joints) and improves the quality of life 
(4,5).1,005,358,368 IU F9 was consumed worldwide in 2012(1). However, about 70-80% 
patients, mostly in developing countries, received inadequate or no treatment because of 
the limited supplies and high costs of either recombinant(r) or pathogen screened, 
plasma-derived (pd-) F9 concentrates, whose average wholesale price is about US$1.18 
per IU(2,6). Of 15 licensed F9 concentrates, 14 are pdF9 which may result in prion and 
virus transmission risks(7); while only one is mammalian cell expression derived, which 
is recommended because of the safety reason (5). Thus, more economical and pathogen 
safe ways to manufacture rF9 are desired. 
Like other Vitamin K dependent proteins of the coagulation cascade, F9 is a complex 
protein made by the liver while occurring in plasma at trace levels of only 5 µg/ml(8). 
The complex biosynthesis of F9 begins with a precursor polypeptide that then undergoes 
a number of post-translational modifications (PTMs): proteolytic cleavage of the 
propeptide, γ-carboxylation, β-hydroxylation, phosphorylation, and glycosylation(9). 
Mammalian cells, like Chinese hamster ovary (CHO) cells can make certain PTMs 
essential to biological activity in a comparable way to hepatocytes such as propeptide 
removal and γ-carboxylation(10-12).  Unfortunately, these are still very low rates of 
synthesis that impede the use of current bioreactor technology by developing countries to 
produce rF9 for biotherapeutic use (6,13).   
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The economical rF9 production is also hindered by the low expression rate and low 
mammalian cell concentrations, about 10
6
 cells/ml culture (6,14). To offset the restriction 
caused by low cell concentration in bioreactors, we and other groups have shown that the 
three orders of magnitude higher cell density of the mammary gland and demonstrated 
expressing bioactive rF9 at higher levels in pig milk than is currently done in the culture 
media of stainless steel bioreactors(6).   
While the mammary gland is a prodigious vehicle for producing recombinant proteins at 
high concentrations, the combination of species specificity of the mammary gland to 
make certain PTMs while providing sufficient milk for production is still challenging. 
Transgenic animals, including mice and sheep, produced recombinant human F9 in their 
mammary glands, limited amount of bio-active F9 was secreted into the milk(14-16). 
Importantly, our previous work has shown that the pig has combined capability to make a 
diversity of PTMs which include glycosylation, a high volume of milk production (200-
400 liters per year) (6,17,18) and is also multiparous. These features make it an efficient 
livestock in which to do further multiple gene, bioengineering by using somatic cell 
nuclear transfer (SCNT) technology(19). Examples of the PTM capabilities of the pig has 
been demonstrated by the expression of human F8 (20), protein C (21) , von Willebrand 
factor (VWF) (22) and F9 (9,23). In addition, the pig has the advantage as a specific 
pathogen free source of human biotherapeutics because it is not sensitive to prion 
exposure. Other livestock such as cows may need the PRNP gene required for the 
development of prion diseases to be knocked out to help ensure a prion free condition 
(24).   
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In order to fully take advantage of the high translational and secretory throughput of the 
mammary gland, higher PTMs processing rates must be made by multiple enzymes 
engineered into the transgenic livestock. In perturbing the expression of rF9 ten-fold from 
0.2 g/l to greater than 2 g/l, about 10-30% rF9 had pro-peptide attached. The defective 
propeptide cleavage results in destabilizing the calcium-induced Gla domain 
conformation change and no pro-coagulation activity of pro-peptide attached FIX (25). 
Furin or paired basic amino acid cleaving enzyme (PACE), a Ca
2+
 dependent serine 
protease of the PC family, is involved in processing pro-peptides at dibasic sites with 
consensus sequence Arg-X-Lys/Arg-Arg (RXK/RR) (26). This includes the precursors of 
hormone: pro-nerve growth factor β(27), pro-insulin, pro-albumin, pro-complement 
C3(28,29), pro-von Willebrand factor(30), pro-factor IX(31) and protein C (32). Furin is 
localized primarily to the trans-Golgi network (TGN)(33-36), and also traffics between 
TGN and cell surface, and ER retention of furin blocked it activation resulting in no 
bioactivity (37,38). The order in location of carboxylase (ER) and furin (TGN) in vivo 
assure the pro-peptide removal after the carboxylation formed. 
In terms of bioengineering of the mammary gland of a mouse, Drews et al. used furin 
under the control of the murine Whey Acidic Protein (mWAP) to increase the proteolytic 
processing of internal dipeptides of protein C(32). We here present the bioengineering of 
the pig mammary gland to provide sufficient furin activity to completely remove the pro-
peptide and convert the inactive pro-rF9 to mature and active rF9 zymogen form at 
expression rate of 2 g/L.   
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METHODS 
All buffer components were purchased from VWR International LLC (Radnor, PA) or 
Thermo Fisher scientific (Waltham, MA) or Sigma (St. Louis, MO) unless otherwise 
stated. All of the following solutions and media used in fetal fibroblast collection, 
transgenic cells producing, oocyte maturation, SCNT, and embryo reconstruction were 
filtered by using a 0.22 µm filter. All animal procedures were performed with an 
approved University of Missouri Animal Care and Use (ACUC) protocol. Unless stated 
otherwise, the following purifications were performed on a BioCAD Vision 
chromatography station (Applied Biosystems, Grand Island, NY). In order to minimize 
degradation, purification processes were performed at 4°C. The pd-F9 (Mononine, CSL 
Behring, King of Prussia, PA) and CHO-rhF9 (BeneF9, Pfizer, New York City, NY) used 
in the study were expired for clinical use however when used in experiments, exhibited 
full pro-coagulant activity. Both were kind gifts from James Brown (Lincoln, NE)      
Fetal Fibroblast Collection 
Landrace fetal fibroblasts cells (FFCs) were collected as described(39) with some 
modifications. Briefly, after removing the head, intestine, liver, limbs, and heart, the fetus 
was minced and digested individually in 20 mL of digestion media (Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 15% (v/v) FBS, 200 units/ mL collagenase 
and 25 Kunitz/mL DNaseI) for 5 hrs at 38.5°C and 5% CO2 in air. Digested cells were 
washed with DMEM, 15% fetal bovine serum (FBS) (Hyclone, Logan, UT) with 10 
µg/mL gentamicin, cultured overnight, then collected and frozen at −80 °C in aliquots in 
FBS with 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen. 
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Production of gene constructs  
The production of the WAP6FIX and WAP5Furin transgenes has been described in detail 
previously (32,40) and showed in Fig. 1A. F9 and furin constructs were linearized by 
NotI. After enzyme digestion, constructs were gel purified and stored at -20°C until 
transfection. 
                              
 
Fig.1. A. Transgene constructs schematic for WAP6FIX and WAP5Furin. The 
cDNA for human FIX and truncated human furin cDNA were placed under control of the 
4.1 or 2.5 kbp mammary specific Whey Acidic Protein (WAP) promoters, respectively. B. 
Domain schematic of the primary structure of both native and truncated human 
furin. Domains indicated: Signal Peptide a.a.1-26 (SP); Propeptide a.a. 27-107 (PRO);  
Subtilisin-like Serine Protease domain a.a.132-447; activation maturation domain 
a.a.484-570 (P);  Cystine-rich region (CRR); trans-membrane domain (TM); Cytoplasmic 
domain a.a. 759-762 (Cyt); Trans Golgi Network Signal domain (TGN). 
 
 
 
 
A 
B 
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Production of transgenic cells 
Early passage number Landrace FFCs (1-2) were cultured in cell culture medium 
(DMEM supplemented with 15% (v/v) FBS, 2.5 ng/mL basic fibroblast growth factor 
(Sigma) and 10 μg/mL gentamicin.) overnight and grown to 75–85% confluency. Media 
was replaced 4 hours prior to transfection. FFCs were washed for 1–2 min with 
phosphate buffered saline (Invitrogen) and harvested with 0.05% trypsin-EDTA 
(Invitrogen; 1 mL per 75cm
2
 flask). Cells were resuspended in cell culture medium, 
pelleted at 600 × g for 10 min, resuspended in 10 mL Opti-MEM (Invitrogen), and then 
quantified by using a hemocytometer and repelleted. Cells were resuspended in 
transfection media (75% cytosalts [120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4; pH 
7.6, 5 mM MgCl2] (van den Hoff et al. 1992) and 25% Opti-MEM (Gibco BRL Grand 
Island, NY)) and quantified again and the cell concentration was adjusted to 1×10
6
 
cells/mL. Two hundred microliters cells were co-transfected by electroporation with 
linearize F9 (2μg), furin (2μg) constructs. Each electroporation utilized three consecutive 
250-V, 1-ms square wave pulses administered through a BTX ECM 2001 (BTX, San 
Diego, CA) in 2 mm gap cuvettes. After electroporation, cells were plated in 100 mm 
dish at the concentration of 3000 cells per dish in cell culture medium. After 36 hours, 
cells were selected by the addition of geneticin (G418; 400 μg/mL) for 10-14 days until 
the formation of cell colonies. Genomic DNA from the cell colonies was used to verify 
the presence of all two genes by PCR. These cells then were stored in liquid nitrogen 
until used as donor cells for somatic cell nuclear transfer (SCNT).   
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Oocyte Maturation, SCNT, and Embryo Reconstruction 
Fibroblast cells identified to have integration of both F9 and furin transgenes were used 
as donor cells for SCNT into enucleated oocytes followed by electrical fusion and 
activation (39). In brief, cumulus-oocyte cell complexes (COCs) were received in Phase I 
maturation medium from ART Inc. (Madison, WI) approximately 24 hours after harvest. 
COCs were then cultured in fresh Phase II maturation medium for 16 h. Maturation was 
in a humidified atmosphere of 5% CO2 at 38.5°C. Expanded COCs were then vortexed in 
0.1% hyaluronidase in Hepes-buffered Tyrode’s medium containing 0.01% polyvinyl 
pyrrolidone for 4 min to remove the cumulus cells. Only oocytes having a visible first 
polar body (PB) with uniform cytoplasm were selected and placed in fresh manipulation 
medium (25 mM Hepes-buffered TCM199 with 3 mg/mL bovine serum albumin (BSA)) 
containing 7.5 μg/mL cytochalasin B overlaid with warm mineral oil. SCNT was 
conducted (39) by removing the PB, MII chromosomes and a small amount of 
surrounding cytoplasm of the oocyte by using a beveled glass pipette with an inner 
diameter of 17-20 μm. After enucleation, a donor cell was injected into the perivitelline 
space and placed adjacent to the recipient cytoplasm. The reconstructed embryos were 
fused and activated with 2 DC pulses (1 sec interval) of 1.2 kV/cm for 30 µsec provided 
by a BTX Electro-cell Manipulator 200 in fusion medium (0.3 M mannitol, 1.0 mM 
CaCl2, 0.1 mM MgCl2, and 0.5 mM Hepes, pH adjusted to 7.0–7.4). After fusion and 
activation, only the fused embryos were cultured into four well plates (Nunc, Denmark) 
containing 500 µL of PZM3 with 0.3% BSA and 500 nM Scriptaid at 38.5 °C and 5% 
CO2 in humidified air for 14 to 16 hours, until embryo transfer(41).  
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Embryo Transfer and piglet production 
More than 100 SCNT zygotes were surgically transferred to the oviducts of each 
surrogate on the day of, or one day after, the onset of estrus. Ultrasound was used to 
monitor the pregnancy. Piglets were delivered via cesarean section from surrogates by 
day 114-116 of gestation. Piglets are processed immediately and tissue samples were 
collected for establishment of cell lines and PCR genotyping. Piglets were then hand-
raised until weaning (3-4 wks of age). After confirming genotype and reaching sexual 
maturity, the founders with both F9 and furin cDNA were mated to wild type pigs for 
production of animals for milking and phenotyping.  
PCR Genotyping Assays 
The integration of transgenes in the founders and offspring was conducted by using 10 ng 
of genomic DNA for each 25 µL PCR reaction (Mastercycler Pro; Eppendorf, Hauppauge, 
NY). GoTaq polymerase (Promega, Madison, WI) was used as recommended by the 
manufacturers. PCR primers (Table 1) were used in under PCR cycling conditions of: 
95°C for 3 minutes followed by 30 cycles at 95°C for 15 seconds, 58°C for 30 seconds, 
and 72°C for 45 seconds.   
Gene Primers 
Fragment 
size 
F9 
Forward:  5’-TACCTCTTTGGCCGATTCAG-3’ 
430bp 
Reverse:  5’-GCTCCTTCATTTTCTCCGCT-3’, 
Furin: 
Forward: 5’- GCGAGAGGACCGCCTTTATCAAAGA-3’ 
293bp 
Reverse:  5’-TGGAAATCACCTGTGGCTGTCTTGC-3’ 
eNOS 
Forward:  5’ -ACGAGCCTCCAGAACTCTTTGCTT-3’ 
243 bp 
Reverse:  5’- TTTCCAGCAGCATGTTGGACACTG-3′ 
Table 1.  PCR Genotyping primers and fragments size for transgenic pigs 
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Content and quality of genomic DNA loaded in the PCR reaction was confirmed by 
amplification of the endogenous swine eNOS gene using the following PCR conditions: 
95°C for 3 minutes followed by 30 cycles at 95°C for 15 seconds, 59°C for 30 seconds, 
and 72°C for 45 seconds. 
Pig milking  
Transgenic pig milk was collected as previously described (42). Milk samples were 
collected twice daily on the following days (D5-10, then every three days until D35). 
Piglets were removed from the mother 30 minutes before milk sample collection and 
returned following sample collection. An injection of Oxytocin was given to the sow 10-
15 minutes before sample collection.   
Sodium Dodecylsulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Samples were analyzed by SDS-PAGE stained with colloidal Blue gel stain (Invitrogen, 
Carlsbad, CA, USA) using Invitrogen 12% Bis-Tris Novex acrylamide precast gels and 
the Invitrogen Surelock XL apparatus (200 Volts for 1 hour). Briefly, samples were 
mixed with 4x LDS sample buffer (Invitrogen) and deionized water followed by heating 
at 74 °C for 10 min. For reduced gels, samples were mixed with 10x reducing agent 
(Invitrogen) prior to heating.  
Western Blot  
The gels were electro-blotted onto poly vinylidene fluoride (PVDF) membranes using a 
BioRad  Transblot SemiDry Transfer Cell (Richmond, CA) for 30 min at 25 volts.  For 
total F9,including all F9 species, blots were probed by rabbit polyclonal antibody (Pab) 
anti-F9 (F0652, Sigma-Aldrich St. Louis, MO); The furin was detected by using rabbit 
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Pab anti-furin (476-490) (F8806, Sigma-Aldrich St. Louis, MO); The mouse monoclonal 
antibody (Mab), PROFIX 3D2.6H12 (Green Mountain Antibody, Burlington, VT), was 
used in probing pro-peptide of F9. The secondary antibody (HRP-conjugated) anti- rabbit 
(A9169) and mouse (A4416) IgG (Sigma-Aldrich St. Louis, MO) was used to detect the 
primary antibody respectively. The chromogenic DAB substrate (Thermo, Rockford, IL) 
was used in color developing. 
Quantification of Recombinant Human Factor IX (rF9) and Recombinant Human 
Pro-peptide attached Factor IX (pro-rF9) in Transgenic Milk  
Western blot was performed as described before. Mononine or purified pro-rF9, as 
calibrator, was loaded along with the transgenic milk samples (triplicated). The 
concentration mononine or pro-rF9 was determined by measuring the optical density at 
280 nm in a 1 cm quartz cuvette and using an extinction coefficient, ε1% =13.4. The 
pictures of the blots were analyzed by using the Image J(43,44). The amount of rF9 and 
pro-rF9 was then calculated by using the standard curve created by the calibrators. 
Scaled-up Processing Pro-rF9 in Transgenic Milk by Incubating with Rfurin Co-
expressed Transgenic Milk before Purification 
Whole transgenic milk with rfurin co-expressed sample was first added to heparin 
sepharose fast flow (FF) (GE Healthcare Bio-Sciences AB, Sweden) resin at 1:1 (v/v) 
ratio and incubated for 30 min at 4  C. The supernatant was collected (F9 depleted) and 
was then incubated with the whole transgenic milk with only rF9 expressed at 1:4 (v/v) 
ratio for 2 hour. All above milk samples were not treated with EDTA and any protease 
inhibitors.  
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Scaled-up Purification of High Acidic Recombinant Human Factor IX from 
Transgenic Swine Milk  
High acidic rF9 was purified using the procedures adapted from previous study(23). The 
clarified transgenic milk samples was first diluted with the loading buffer (20 mM Tris, 
50 mM NaCl, pH 7.4) at 1:3 ratio then loaded onto a heparin hyper D column, 26cm ID 
X 20 cm L (GE Healthcare Bio-Sciences AB, Sweden). The impurities were washed out 
by increasing [NaCl] to 200 mM, then the whole rF9 was eluted by increasing [NaCl] to 
500 mM. The flow rate of the chromatography was 4 ml/min. The enriched rF9 sample 
was further loaded on the phenyl 650C column, 26 cm ID X 20cm L (Tosoh Bioscience, 
LLC) in the loading buffer (500 mM NaCl), the rF9 was collected in the flow through 
with flow rate at 4 ml/min. The rF9 sample was loaded on Q sepharose fast flow column 
(GE Healthcare Bio-Sciences AB, Sweden), 26 cm ID X 20cm L. The low acidic F9 
population was washed out by increased [Ammonium acetate] to 537 mM, and the high 
acidic F9 was eluted at [Ammonium acetate] at 800 mM with the flow rate at 4 ml/min. 
All buffer exchanges of rF9 samples were performed by using the tangential flow filter 
(TFF) system (10 kDa MWKO, Pall Corporation,  Port Washington, NY). All steps were 
performed at 4 °C.  
Separate Active rF9 from High Acidic rF9 population by High Pressure Liquid 
Chromatography-Size Exclusion Chromatography (HPLC-SEC) 
The high acidic rF9 was exchanged into SEC running buffer (20 mM Tris, 200 mM NaCl, 
10 mM CaCl2, pH 7.4) by using the Minimate tangential flow filtration systems  with 10 
kDa molecular weight cut off (MWCO) membrane (Pall Corporation,  Port Washington, 
NY) or Amicon tube (10 kDa MWCO) (EMD Millipore, Billerica, MA). F9 sample was 
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loaded on a TSK gel G3000SWXL, 7.8 mm ID x 30 cm, 5 µm (particle size), equipped 
with a guard column, 6 mm ID x 4 cm, 7 µm (particle size), (Tosoh Bioscience, LLC). 
The flow rate was 0.5 ml per min and duration of the run was 45 min with all major peaks 
eluting before 35 min. The chromatography were performed by using Knauer Smartline 
chromatography apparatus, including Manger 5000, Pump 1000 and UV Detector 2600 
(Berlin, Germany), equipped with a Gilson FC 204 fraction collector (Middleton, WI). 
Both columns were equilibrated and run with 20 mM Tris base, 200 mM NaCl, 10 mM 
CaCl2, pH 7.0. The fractions of each peak were pooled together for further analysis. 
Purification of Pro-rF9 and rF9 from Transgenic Milk 
Transgenic milk, no rfurin co-expressed with rF9 (K96 lactation day 24), was used to 
purify both rF9 and pro-rF9 subpopulation. The whole rF9 population (including both rF9 
and pro-rF9 subpopulation) was purified by using the heparin hyper D column as 
described above. Then it was loaded on the immunoaffinity colum, mouse monoclonal 
antibody (Mab) anti-propeptide of pro-rF9(Green Mountain Antibody, Burlington, VT) 
immobilized Protein G Sepharose FF(GE Healthcare Bio-Sciences AB, Sweden) at 1 mg 
Mab/ml resin , 10 mm ID X 127 mm L (10 mL). The loading buffer was 20 Mm Tris, 50 
mM NaCl, pH 7.4; the wash buffer was the loading buffer with 500 mM NaCl with the 
flow rate at 150 cm/hr. The rF9 subpopulation was achieved in the flow through. The 
pro-rF9 was eluted by using 0.1 M Glycine, pH 2.8 and then neutralized by 1:10 (v/v) 1 
M Tris, pH 8.5 to the eluate. 
Quantitation of total factor IX activity 
Total F9 activity was determined using the activated partial thromboplastin time (aPTT) 
assay (45). Briefly, 50µl each of PTT Automate 5 reagent (Diagnostica Stago, Inc., 
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Parsippany, NJ, USA), factor IX deficient plasma (George King Bio-Medical, Overland 
Park, Kansas, USA), and a sample of interest were added to a cuvette and incubated at 
37 °C for 3 min. 50 µL of 25mM CaCl2 (Sigma) was then added and the clotting time 
was measured using the STart Hemostasis Analyzer (Diagnostica Stago, Inc., Parsippany, 
NJ). The normal human plasma (Diagnostica Stago, Inc., Parsippany, NJ) was used as the 
standard, assigning 1 unit of F9 clotting activity per milliliter of plasma. The 
concentration of purified rF9 was determined by measuring the optical density at 280 nm 
in a 1 cm quartz cuvette and using an extinction coefficient, ε1% =13.4. 
NH2-terminal sequencing of the plasmin cleavage products of F9 
Amino acid sequencing was performed at the University of Nebraska Medical Center, 
Protein Structure Core Facility. Protein samples were subjected to SDS-PAGE and 
transferred to PVDF as described above. The membrane was stained with Colloidal Blue 
and bands excised and subjected to Edman degradation using Applied Biosystems 
Procise protein sequencer, a Hitachi 8800 Amino Acid Analyzer and a Michrom MAGIC 
HPLC equipped with a Diode Array Detector. 
Purification of Recombinant Truncated Human Furin (rfurin) from Transgenic 
Milk with Rfurin Co-expressed  
Transgenic milk sample (R1014, lactation day 5-22 pool), having rfurin co-expressed, 
was first diluted with DEAE loading buffer, 20 mM HEPES, 50 mM NaCl, 2 mM CaCl2, 
0.1% (w/v) Brij-35, pH 7.5, at 1:4 (v/v) ratio and centrifuged at 12000 rpm, 4 °C for 20 
min. The supernatant (clarified milk) was loaded on the DEAE fast flow column (GE 
Healthcare Bio-Sciences AB, Sweden), 10 mm ID X 127 mm L (10 ml) with the flow 
rate at 150 cm/hr; and the furin fraction was eluted by increasing [NaCl] to 140 mM. The 
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DEAE eluate was exchanged to the CHT binding buffer (20 mM HEPES, 2 mM 
Na2HPO4, 0.1% (w/v) Brij-35, pH 7.5) and loaded on the Ceramic Hydroxyapatite, CHT 
(Bio-Rad, Hercules, CA) column, 10 mm ID X 127 mm L (10 ml) at 150 cm/hr. The flow 
through, which had rfurin, was collected. Rfurin fractions were exchanged to the Q 
Sepharose binding buffer (20 mM HEPES, 50 mM NaCl, 2 mM CaCl2, 0.1% (w/v) Brij-
35, pH 7.2) and loaded onto the Q Sepharose FF (GE Healthcare, Bio-Sciences AB, 
Sweden) column, 10 mm ID X 127 mm L (10 ml) with the flow rate at 150 cm/hr; the 
furin fraction was eluted at 140 mM NaCl. Final sample was exchanged to 20 mM 
HEPES, 2 mM CaCl2, 0.1% (w/v) Brij-35, pH 7.5. 
Quantification of Activity of Furin 
Activity of Furin in Milk—Fluorometric assays were carried out essentially as described 
(46). Whole milk sample was diluted 1:50 to 1:200 with assay buffer (20 mM HEPES, 2 
mM CaCl2, 0.1% (w/v) Brij-35, pH 7.5). Calibrator is the 7- amino, 4-Methyl Coumarin 
(AMC), concentration is from 0.39 uM to 25 uM in assay buffer. 50 uL 100 uM substrate, 
L-PyroGlu-Arg-Thr-Lys-Arg-AMC (pERTKR-AMC) (R&D systems, Minneapolis, MN, 
USA) was incubated with the 50 uL diluted sample at room temperature. Fluorescence 
was measured by Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies, 
USA) at λex 342 nm; λem 440 nm with kinetic mode for up to 20 mins. The control 
consisted of substrate and assay buffer. 1 Unit of furin is equal to 1 pmol AMC/min in the 
above conditions. 
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Cleavage of Pro-peptide of Pro-rF9 by Partial Purified Recombinant Truncated 
Human furin (rfurin) in vitro 
Add 346 µL rfurin sample (43.35 U/mL), total activity was 15 U (cleaved 15 pmol 
prpeptides/min), to 200 µg (0.2 mg/ml, total 3500 pmol pro-rF9) purifided pro-rF9 
described above in furin activity assay buffer (20 mM HEPES, 2 mM CaCl2, 0.1% (w/v) 
Brij-35, pH 7.5). At each time point (0, 30min, 1, 2, 4, 8 and 24 hr), reaction was 
quenched by taking 20 µL sample and mixed with 4 X SDS-PAGE sample buffer (with 
or without 10 X reduced agent) for non-reduced, reduced SDS-PAGE respectively. 
Additional 50 µL sample was quenched by 50 µL 20 mM sodium citrate, pH 7.4 for the 
F9 activity (aPTT) assay. The reaction was in room temperature (25  C) 
 
RESULTS 
Generation F9 and Furin Co-expressed Pigs  
Thirteen live female F9 transgenic piglets were born from 5 litters. Six of 13 pigs were 
positive for F9 and FURIN transgenes. Fifteen male F9 transgenic piglets were born from 
3 litters and all of them were positive for F9 and furin transgenes (Table 2).  
Production of Female Transgenic Offspring for Milk Collection and Mendelian 
Inheritance of the Transgenes  
Male transgenic founder lines, Line A (78-2, 78-4), Line B (79-2) and Line C (80-4) were 
mated with wild type Landrace sows to produce the female offspring for milk production 
to test the foreign protein expression. Sixty-four offspring were produced from 5 litters. 
Of those 64 offspring, 26 were positive for F9 and FURIN (Table 3, Figure 2).  The 
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percentage of transgenic positive offspring is 41% which is closed to the expected ratio of 
50% for Mendelian inheritance of the transgenic loci. Transgenic males were mated to a 
wild-type boar and allowed to farrow. Milk samples were collected from all three 
integration sites (Line A, B and C). 
Table 2.  Summary of production of rF9 transgenic founder pigs 
 
Founder Litter number offspring F9 and Furin Wild type 
78-2 122 16 6 10 
78-4 123 15 1 14 
79-2 125 10 4 6 
80-4 23, 129 23 15 8 
Total 5 64 26(41%) 38 (59%) 
Table 3.  Male founders mated to the wild type sows for production of female transgenic 
offspring 
 
Litter Litter size Sex Transgenic Wild type 
65 1 Female 0 1 
66 1 Female 0 1 
67 6 Female 4 2 
68 4 Female 1 3 
69 1 Female 1 0 
78 6 Male 6 0 
79 5 Male 5 0 
80 4 Male 4 0 
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Fig. 2. Genotyping of F9 and Furin in the piglets of litter 78 and 79 by PCR. Eleven 
piglets from the two litters were carrying both transgenes; eNOS was used as endogenous 
gene control. Lane 1- 6, 6 piglets of litter 78; lane 7, positive control; lane 8, wild type 
genomic DNA; lane 9, negative control; lane 10, ladder; lane 11-15, 5 piglets of litter 79; 
lane 16, positive control; lane 17, wild type DNA; lane 18, negative control.  
Limited Processing of the Pro-peptide of rF9 by Endogenous Porcine Furin in 
Mammary Epithelium  
The total rF9 expression rate was high in the transgenic milk, from 1.50 ± 0.02 g/L 
(Avg.±SD, n=3) to 2.30 ± 0.05 g/L (Avg.±SD, n=3) (Table 4). Western blot developed by 
antibody anti pro-peptide of human factor IX confirmed the existing of pro-rF9, which 
was not fully processed by endogenous porcine furin, in the transgenic milk (Fig. 3); and 
there was 9% to 27% pro-rF9 of total rF9 in the transgenic milk sample (Fig. 3, Table 4). 
The molecular weight of purified pro-rF9 was 57 kDa, 2 kDa more than the rF9 (Fig. 5A, 
lane 1). N-terminal amino acid sequencing showed the result, Thr-Val-Phe-Leu-Asp, 
matching the sequence of the pro-peptide of pro-rF9.  
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Fig.3. Western blot of milk samples. Milk samples included rF9 only expressed 
transgenic milk (K75 lactation day 11-23 pool and K101, lactation day 12-29 pool) and 
the rfurin co-expressed transgenic milk (R175 & 179 lactation day 5-35 pool, R180 
lactation day 5-35 pool and R1014 lactation day 5-22 pool). All milk samples were 
diluted with 200 mM EDTA 1: 1 and skimmed as described in methods. Lane 1: K75 
lactation day 11-23 pool; Lane 2: K101, lactation day 12-29 pool; Lane 3: R175 & 179 
lactation day 5-35 pool; Lane 4: R180 lactation day 5-35 pool; and lane 5: R1014 
lactation day 5-22 pool. 2 µL of each milk sample was loaded on each lane. The 55 kDa 
bands indicated the F9 (including the rF9 zymogen and the pro-rF9); the 65 kDa bands 
indicated the rfurin; and the 57 kDa bands indicated the pro-rF9 (the 47 kDa bands were 
unspecific binding) 
No F9 activity was detected for the pro-rF9 (Table 4). No furin antigen was detected by 
the Western blot developed using antibody anti-human furin; neither furin activity was 
detected in the milk sample.  
PIG ID 
Lactation 
Pool 
[Total rF9] 
(mg/ml) 
[Pro-rF9] (mg/ml) 
(Percentage of            
Pro-rF9 %) 
Furin Activity 
(U/ml) 
R175 & 
179 
Day 5-35 2.23 ± 0.07 
Not Detected 
1402 ± 40 
R180 Day 5-35 1.60  ± 0.35 539 ± 217 
R1014 Day 5-22 2.22  ± 0.06 2214 ± 33 
K75 Day 11-23 2.30  ± 0.05 0.21 ± 0.05 (9%) 
Not Detected K96 Day 10-25 1.63  ± 0.36 0.25 ± 0.04 (15%) 
K101 Day 12-29 1.50  ± 0.02 0.40 ± 0.10 (27%) 
Table 4. Amount of total rF9, pro-F9 and rfurin in transgenic milk samples (n=3). 
60 
 
Rfurin Expressing and Processing Pro-peptide of rF9 in vivo  
Not like the endogenous human furin, this truncated rfurin is eliminated transmembrane 
domain, cytoplasmic domain and trans-Golgi network (TGN) signal domain (Fig. 1B). 
This rfurin secretes into the milk, remaining its furin activity, while endogenous furin 
cycled in the TGN of epithelium. The Western blot developed by antibody anti-furin 
showed the rfurin signal, whose molecular weight is about 65 kDa (Fig. 5, lane F). And 
the furin activity reached up to 2214 ±33 U/mL (Avg.±SD, n=3) in transgenic milk 
(R1014, lactation day 5-22 Pool). The expression of rfurin was stable during the lactation, 
and the more furin activity was detected during the late lactation (Fig. 4).  
 
Fig. 4. Furin activity in transgenic milk. The furin activity of R180 transgenic milk 
samples (each lactation day) was measured. 1 Unit of furin is equal to 1 pmol AMC/min 
in the above conditions. The error bars is the standard deviation (n=3) 
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The co-expression of rfurin did not interfere the producing rF9 in transgenic milk, which 
reached 2.23 ± 0.07 g/L (Avg.±SD, n=3) (Table 4). No more pro-rF9 was detected (Fig. 3, 
Table 4). 
Rfurin Processing Pro-rF9 in vitro 
Rfurin was enriched (partially purified) from the transgenic milk sample. ~ 40% furin 
activity was recovered after 4 purification steps (Table 5). N-terminal amino acid 
sequencing of the 65kDa band (on the non-reduced SDS-PAGE) (Fig. 5A, lane F), Asp-
Val-Try-Gln-Glu, matched the mature form of human furin (47). Purified pro-rF9 was 
incubated with partially purified rfurin at room temperature for up to 24 hours. We 
noticed the molecular weight of pro-rF9 shifted about 2 kDa after incubated with rfurin 
on both SDS-PAGE and western (Fig. 5A). Pro-rF9 signal was decreasing, while signal 
on total rF9 (including both pro-rF9 and rF9) remained same on the non-reduced western 
blots (Fig. 4B). Also, we noticed that the F9 specific activity of the sample increased after 
incubated with rfurin (Fig.5C). 
Sample Volume (ml) 
Activity 
(U/ml) 
Total Activity 
(U) 
Activity 
Recovery % 
Whole Milk 10 1925 19247 100 
Clarified Milk 45 323 14527 75 
DEAE Elution 85 142 12040 63 
CHT Flow 
Through 
175 50 8666 45 
Q Elution 135 53 7209 37 
Table 5. Purification table of isolation rfurin from transgenic milk (R1014 lactation day 
5-22 pool) 
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Fig. 5. RFurin cleave pro-peptide of pro-rF9 in vitro. A. Non-reduced and Reduced 
SDS-PAGE. B. Non-reduced western blot anti-FIX and proFIX. On non-reduced gel, lane 
F is partially purified rfurin sample and arrow pointing rfurin (65 kDa); On reduced gle, 
lane F is partially purified rfurin sample which loaded as same amount as in the reaction. 
The 65 kDa band is the band (~55 kDa) on non-reduced gel, not the rfurin. Lane 1: 
Purified pro-rF9 (57 kDa), same amount as the reaction loaded on the following lanes. 
Lane 2-8: Furin processing pro-rF9 in vitro reaction time= 0, 30 min, 1, 2, 4, 8 and 24 hr. 
C. Specific activity of pro-rF9; pro-rF9 and total rF9 content in the rfurin processing pro-
rF9 reaction sample. 
 
Scaled-up Purification of Active rF9 from Transgenic Milk 
Both transgenic without rfurin co-expressed (K82, K89, K92 and K102 Pool) and with 
rfurin co-expressed (R185 Pool) were used to purify active rF9. The pro-rF9 in the 
transgenic milk was processed by incubated with rF9 depleted transgenic milk with rfurin 
co-expressed. The yield of active rF9 from the non- and rfurin co-expressed transgenic 
milk were 31.6 mg (active rF9) out of 1479 mg (total rF9) and 22.9 mg out of 1409 mg 
respectively; And there was no significant difference between the F9 specific activity of 
both active rF9 (Table 6). 
Transgenic 
Milk 
Heparin 
Eluate 
(mg) 
Acidic Eluate (mg) 
/ Recovery % 
Active rF9 (mg)  / 
Recovery % 
Specific 
Activity 
(U/mg) 
No rfurin  
co-expressed 
1479 119 / 8 % 31.6 / 2 % 226 ± 42 
Rfurin  
co-expressed 
1409 90 / 6 % 22.9 / 2 % 216 ± 14 
Table 6. Comparison of rF9 from both transgenic without rfurin co-expressed (K82, K89, 
K92 and K102 Pool) and with rfurin co-expressed (R185 Pool) milk by scaled-up 
purification.  
 
Discussion 
The demand of producing F9 proteins in a safe and highly efficient manner has increased. 
Based on the data from the World Federation of Hemophilia (Montreal, Canada), the 
consumption of F9 was approximately 250,100,000 U in the United States and 
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1,005,358,368 U worldwide in 2012(1). And we also need to consider the about 80% 
patients in developing and undeveloped area could not afford the high cost of the F9 
concentrates. So the need for F9 concentrates is way more than the current consumption 
(3,48). Besides the high cost of hemophilia treatment, proteins derived from human 
plasma carry with them the risk of transmission of blood-borne diseases and infections(3). 
Considering bio-safety reasons, the application of recombinant human F9 products is 
widely recommended(49). A transgenic animal bioreactor is an attractive system for 
meeting the need for therapeutic recombinant proteins. Compared with other recombinant 
protein expression systems, transgenic animals have the ability to produce the biological 
active proteins approximately a 10-fold higher concentration of the target protein(6). In 
addition, a transgenic farm with a single purification facility should not cost more than 
US$80 million(50). However, building a large-scale (10,000 liter bioreactor) 
manufacturing facility for a mammalian cell expression system is time consuming and 
costs US$ 250–500 million(50). One successful example is ATryn, an anticoagulant, the 
first ever biologic product produced by a genetically engineered (GE) animal – a goat(51), 
which was approved by FDA to be used for the prevention of blood clots in patients in 
2009. 
The recombinant human F9 was expressed in several mammary gland of transgenic 
animals by using the SCNT technology. Very low amounts of inactive F9 have been 
detected in the transgenic sheep milk (52) . Zhang et al reported that the highest 
production of F9 in goat milk was 13.7 ng/mL 3 days after transfection plasmid DNA 
directly into the mammary gland lobule of a lactating goat and > 90% rF9 protein in milk 
appeared to be a gamma-glycosylated and biologically active (53). In mice, up to 60 
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mg/L at 50% of biologically active F9 have been reported (54). In contrast to the species 
listed above, Van Cott et al reported that full specific activity rF9 produced by porcine 
mammary gland cells of F9 was only 200 mg/L in the milk(55). Lindsay et al made pigs 
capable of producing rF9 at 2-3 g/L (23). However, with the 10-fold increasing in 
expression rate, the active rF9 decreased to only 10-20%, in addition, we noticed about 
10-30% rF9 had pro-peptide attached, which was no pro-coagulation activity. The low 
percentage of active rF9 in total over-expressed rF9 is because of the rate limited 
enzymatic PTMs after nascent rF9 synthesis in mammary epithelia. To increase the yield 
of active rF9 by converting no-active pro-rF9 into active rF9 zymogen, we bioengineered 
the pig mammary gland by introducing truncated human furin gene to process the 
excessive propeptide. Three male founder lines, Line A (78-2, 78-4), Line B (79-2) and 
Line C (80-4) were mated with wild type landrace sows to produce the female offspring 
for milk production. Sixty four offspring were obtained in 5 litters (Table 3). Among 
these piglets, 26/64 (41%) expressed both rF9 and rfurin. Offspring of were either 
carrying two genes or totally wild type (Table 3) which implies linkage, and that the 
multiple genes might be integrated as clusters. The highest expression level of rF9 was 
2.2 mg/mL milk in pig (R1014), 76-fold higher than production cell line which was 30 
µg/mL(56); and the furin activity in the same milk was more than 2000 U/mL. No 
significant difference in rF9 level compared to the pig (K75) without rfurin co-expressed. 
This indicates that the co-expressing rfurin did not suppress the rF9 expression. In 
contrast to the milk without rfurin co-expressed, no pro-rF9 was detected in the milk with 
rfurin co-expressed (Table 3). Unlike the endogenous furin, the co-expressed truncated 
rfurin was no transmembrane and following domain (Fig. 1B), so this rfurin secreted out 
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the cell rather than the endogenous furin cycled in the trans-Golgi network (TGN). This 
secreted rfurin not only processing nascent rF9 in cell but cleaving pro-peptide in the 
milk as well (Fig. 5). Because the rfurin does not have the transmembrane, which anchors 
the furin on the TGN membrane, we worried the over expressed rfurin moved back into 
the ER removing propeptide, which required by the carboxylase, before or during the ɤ-
carboxylglutamic acids synthesis, which is required for F9 activity. The active rF9 was 
purified from both milk samples, with and without rfurin co-expressed, by using the same 
purification procudures (except the pro-peptide processing). The overall yield of active 
rF9 was similar, which indicated the co-expressed rfurin not interfering the carboxylation 
of glutamic acids. We also noticed in the 10-20% active rF9 subpopulation, almost half 
was activated rF9 or degraded rF9, which was active as rF9 zymogen before activation 
and/or degradation. This was partially caused by protease in milk activating and degraded 
rF9 during processing pro-rF9 in vitro. With the co-expressed the rfurin, the in vitro 
processing pro-rF9 was eliminated, and milk could be treated with protease inhibitors (i.e. 
ε-aminocarporic acid and benzamidine). The yield of active rF9 could further increase by 
decreasing the activation and degradation of rF9 during the processing. 
In summary, we increased the quality of rF9 by co-expressed rfurin removing the pro-
peptide of pro-rF9. rF9 was expressed at a level of 2.2 g/L of milk, and no pro-rF9 was 
detected in the milk. The consumption of rF9 in the U.S. can be estimated at 1.25 kg/year 
(250,100,000 U); and world consumption, at 5 kg/year(1). At 2 g/L rF9 expression rate 
and 400 L milk year
-1
 pig
-1
, and the yield of purified active rF9 zymogen, about 70 
transgenic pigs could meet US’s market and about 270 transgenic pigs can produce 
enough rF9 for the entire world. 
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ABSTRACT  
Hemophilia B is a congenital bleeding disorder caused by the deficiency of functional 
coagulation factor IX (FIX). The current treatment is restricted to the protein replacement, 
including the on-demand or prophylaxis. In 2012, approximately 1 billion FIX 
concentrates were consumed by 28,008 hemophilia B patients worldwide. However, still 
about 80% patients, mostly in developing countries, receive inadequate or no treatment 
because of unavailable or unaffordable FIX concentrates. Consider the plasma derived 
FIX transmitting blood-borne pathogen, recombinant human FIX is recommended. More 
than 99% of consumed FIX concentrates was recombinant in United States. Our lab 
reported expressing recombinant human FIX (tg-FIX), 2-3 g/L with 10-20% active FIX, 
in milk by mammary gland of transgenic pig with lab scale purification developed. In this 
study, large scale purification protocol was established. The brand new camelid IgG 
based immunoaffinity chromatography efficiently in capture the whole tg-FIX population 
in the milk and the high pressure liquid chromatography effectively separate the active 
tg-FIX from non-active tg-FIX and activated tg-FIX subpopulation. 4 chromatography 
isolated active tg-FIX with similar specific activity as plasma derived FIX. 
INTRODUCTION 
Hemophilia type B (Christian disease) is a congenital bleeding disorder caused by the 
deficiency of coagulation factor IX (FIX). 28,008 patients has been diagnosed with 
hemophilia B in 2012 worldwide(1).  The ideal treatments for hemophilia B patients are 
prophylactically, which significantly reduces complications and improves the quality of 
life (2), or the on-demand replacement of blood FIX when bleeding episodes occur (3). In 
2012, about 1 billion IU of FIX concentrates was consumed worldwide(1). However, 
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actual need of the FIX supply could be much more than the reported number, since 70-80% 
patients received inadequate or no treatment because of the high price of the FIX 
concentrates (4). Up-to-date, 14 plasma derived (pd-) and 1 recombinant human FIX 
concentrates are licensed and commercially available on the market (3). Consider the 
transmission of blood-borne diseases and infections, the recombinant human therapeutic 
protein was recommended(5). So, producing the safe recombinant human FIX in an 
economically is required.  
The FIX gene is located on the X-chromosome at q27 and expressed in hepatocytes in a 
highly tissue-specific manner (6,7). The nascent FIX is expressed in a pre-pro form and 
conducted multiple post-translational modifications (PTMs). These PTMs include the 
removal signal peptide, vitamin-K dependent gamma-carboxylation of first 12 glutamic 
acid(8,9), pro-peptide removal(10,11), glycosylation(12-15), beta-hydroxylation of Asp-
64(16), sulfation of Tyr-155(17) and phosphorylation of Ser-158(18-20). The complexity 
of theses PTMs could be performed by certain type of mammalian cells. Chinese hamster 
ovary (CHO) cell, for example, was used for expression the only one recombinant human 
FIX (BeneFIX) on the market approved by FDA. It was characterized having limitations 
on performing those PTMs. Unlike the plasma-derived human FIX, BeneFIX contains a 
mixture of subpopulations with 10, 11 and 12 ɤ-carboxyglutamatic acids, no 
phosphorylation at Ser158, and only 15% sulfation of Tyr155(21).    
Currently, mammary gland of transgenic livestock is a promising bioreactor for 
producing recombinant human proteins economically. Considering the high cell density 
(about 10
9
 cell mL
-1
) of the gland tissue, at the production of  recombinant proteins could 
be 2-3 orders of magnitude greater than density of mammalian cells in steel bioreactors 
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(22). Additionally, the milk production is high, for example, a pig produces about 200-
400 L per year (23,24). However, not all of them are suitable for producing active FIX 
efficiently. No active FIX had been detected in the transgenic sheep milk(25). Zhang et al 
reported that > 90% recombinant protein in milk appeared to be a gamma-glycosylated 
and biologically active but the expression level was only 13.7 ng/mL (26). In contrast, the 
transgenic pig, was reported expressing 2-3 g/L recombinant human FIX (tg-FIX) in the 
milk and 10-20% population with bio-activity(27). Pig is not sensitive to prions; while 
the bovine PRNP gene required for the development of prion diseases(28). In addition, 
cost of establishing a transgenic commercial production herd could be approximately a 
sixth of building a commercial cell-culture facility (29).  So mammary gland of 
transgenic pig could produce the safe recombinant FIX, economically, to meet the need 
for the hemophilia B patient worldwide. In addition, with the drop of the cost of FIX 
concentrates, oral administration of FIX concentration will be an option to replace the 
traditional discomfort, potential for opportunistic infection intravenous. 
After active tg-FIX successfully expressed in the pig milk, the downstream processing is 
important for achieving pure active FIX. However, milk is a challenging feedstock for 
purification because of the large amount native proteins, including the casein (~ 30g/L), 
whey proteins (lactoferrin, α/β-lactalbumin), and serum-passover proteins (serum 
albumin, immunoglobulins, transferrin) and its natures as a multiple-phase mixture, 
including fat, solid and aqueous phases [paper in draft]. Our lab previously made 
progress in developing purification steps by using the heparin-affinity chromatography 
combined with ion-exchange chromatography to isolate the active tg-FIX subpopulation 
from the transgenic pig milk (27). In this study, the more efficient camelid IgG (30) 
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based immunoaffinity chromatography was applied to capture the whole tg-FIX 
population, and the high pressure liquid chromatography size exclusion chromatography 
(HPLC-SEC) was applied to separate active tg-FIX from the low active and activated tg-
FIX subpopulation. In addition, the scaled up protocol was established to meet the large 
quantity of tg-FIX. 
MATERIALS AND METHODS 
All buffer components were purchased from VWR International LLC (Radnor, PA), 
Thermo Fisher scientific (Waltham, MA), or Sigma (St. Louis, MO) unless otherwise 
stated. Reference pd-FIX (Mononine, CSL Behring, USA) was a kind gifts from James 
Brown (Lincoln, NE).  These stocks of were expired for clinical use but when used in 
experiments exhibited full procoagulant activity by one stage clotting assay.  It was 
reconstituted in 20 mM calcium TBS (20 mM Tris, 0.15 M NaCl) pH 7.4 or 10 mM 
EDTA TBS pH 7.4 and then characterized by one stage clotting assay and SDS-PAGE to 
assure homogeneity and biological activity before using in the plasmin degradation 
studies made here. 
Transgenic Milk Collection and Storage  
Transgenic pigs were generated as described previous [paper in draft]. In this study, 
transgenic milk with recombinant human FIX expressed (tg-FIX milk) and transgenic 
milk with recombinant human furin co-expressed with recombinant human FIX (tg-furin-
FIX milk) were both investigated. The transgenic swine milk was collected as described 
with modification whole milk samples were directly stored at -80  C without treatment of 
EDTA or any other protease inhibitors before storage.   
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Cleavage of Pro-peptide of Pro-FIX by Tg-furin in vitro 
Whole tg-furin-FIX milk sample was first added to heparin Sepharose FF (GE Healthcare 
Bio-Sciences AB, Sweden) resin at 1:1 (v/v) ratio and incubated for 30 min. The 
supernatant was collected (FIX depleted) and was then incubated with the whole tg-FIX 
milk at 1:2 or 1:4 (v/v) ratio for 1.5 hour at 4  C. For the scaled up preparation, the whole 
tg-furin-FIX milk was directly incubated with whole tg-FIX milk at 1:4 (v/v) ratio for 2 
hour at room temperature. All above milk samples were not treated with EDTA and any 
protease inhibitors.  
Clarification of Transgenic Milk 
Milk samples, pro-peptide was processed, were mixed with 0.43 M Citrate, pH 6.2 at 1:1 
(v/v) ratio (No PIs treated) or 0.43 M Citrate, 200 mM EDTA, 80 mM ε-aminocaporic 
acid (EACA), 40 mM Benzamidine, pH 6.2 at 1:1 (v/v) ratio (with PIs treated), then 
centrifuged for 2 hours at 9000 rpm at 4  C (Sorvall Evolution RC centrifuge with SLC-
4000 rotor, Thermo). The top fat layer and the bottom casein pellet were removed and the 
middle supernatant was further filtered with cheesecloth.  
Capture of Whole FIX Population in Transgenic Milk by FIX Select  
The milk samples were loaded on the FIX select, camelid Monoclonal antibody anti-
human FIX coupled to Sepharose fast flow (GE), XK26/20 column (GE healthcare, 
Sweden), The flow rate is 6mL/min. And whole FIX population was eluted by elution 
buffer (2M MgCl2). The chromatography was performed at room temperature.   
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Isolation of High Acidic FIX from FIX Select Eluate 
This methods was adapted from previous (27). The total FIX population (FIX select 
elution product) was exchanged into the equilibrium buffer (20mM imidazole, 0.1M 
Ammonium acetate, pH 7.0). The FIX sample was loaded onto Q Sepharose fast flow, 
XK26/20 column (GE healthcare, Sweden). The flow rate is 4 ml/min. The low acidic 
FIX population was washed out by increased [Ammonium acetate] to 537 mM, and the 
high acidic FIX was eluted at [Ammonium acetate] at 800 mM. The Q eluate (EL) was 
further exchanged into the ceramic hydroxyapatite (CHT) equilibrium buffer (20mM 
potassium phosphate, pH 7.2) and loaded on the CHT Type I 40um (BioRad, Richmond, 
CA) XK16/25 column (GE healthcare, Sweden). The flow rate is 3mL/min. The low 
acidic FIX was removed in the wash step by at 65 mM potassium phosphate. Then high 
acidic FIX population was eluted at 200 mM potassium phosphate. Latter portion (about 
80%) of EL (CHT EL 2) was collected.  All buffer exchanges of tg-FIX samples were 
performed by using the tangential flow filter (TFF)10 kDa MWKO (Pall Corporation,  
Port Washington, NY).   
Separate Active FIX from High Acidic FIX population by High 
Performance/Pressure Liquid Chromatography-Size Exclusion Chromatography 
(HPLC-SEC) 
The high acidic tg-FIX was exchanged into SEC running buffer (20 mM Tris, 200 mM 
NaCl, 10 mM CaCl2, pH 7.4) by using the Minimate tangential flow filtration systems 
with 10 kDa molecular weight cut off (MWCO) membrane (Pall Corporation,  Port 
Washington, NY) or Amicon tube (10 kDa MWCO) (EMD Millipore, Billerica, MA). 
For analytical run (≤ 1 mg FIX), FIX sample was loaded on a TSK gel G3000SWXL, 7.8 
79 
 
mm ID x 30 cm, 5 µm (particle size), equipped with a guard column, 6 mm ID x 4 cm, 7 
µm (particle size), (Tosoh Bioscience, LLC). The flow rate was 0.5 ml per min and 
duration of the run was 45 min with all major peaks eluting before 35 min. For large 
preparations (up to 10 mg FIX), FIX sample was loaded on a TSK gel G3000SW  with 
21.5 mm ID x 60 cm, 13 µm (particle size), equipped with a guard column, 8 mm ID x 4 
cm, 10 µm (particle size), (Tosoh Bioscience, LLC). The flow rate was set at 3 ml/min 
and duration of the run was 90 min with all major peaks eluting before 60 min. The 
chromatography were performed by using Knauer Smartline chromatography apparatus, 
including Manger 5000, Pump 1000 and UV Detector 2600 (Berlin, Germany), equipped 
with a Gilson FC 204 fraction collector (Middleton, WI). Both columns were equilibrated 
and run with 20 mM Tris base, 200 mM NaCl, 10 mM CaCl2, pH 7.0. The fractions of 
each peak were pooled together for further analysis.  
Sodium Dodecylsulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Samples were analyzed by SDS-PAGE stained with colloidal Blue gel stain (Invitrogen, 
Carlsbad, CA, USA) using Invitrogen 12% Bis-Tris Novex acrylamide precast gels and 
the Invitrogen Surelock XL apparatus (200 Volts for 1 hour). Briefly, samples were 
mixed with 4x LDS sample buffer (Invitrogen) and deionized water followed by heating 
at 74 °C for 10 min. For reduced gels, samples were mixed with 10x reducing agent 
(Invitrogen) prior to heating.  
Western Blot  
The gels were electro-blotted onto poly vinylidene fluoride (PVDF) membranes using a 
BioRad  Transblot SemiDry Transfer Cell (Richmond, CA) for 30 min at 25 volts.  For 
total FIX,including all FIX species, blots were probed by rabbit polyclonal antibody (Pab) 
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anti-F9 (F0652, Sigma-Aldrich St. Louis, MO); The furin was detected by using rabbit 
Pab anti-furin (476-490) (F8806, Sigma-Aldrich St. Louis, MO); The mouse monoclonal 
antibody (Mab), PROFIX 3D2.6H12 (Green Mountain Antibody, Burlington, VT), was 
used in probing pro-peptide of FIX. The secondary antibody (HRP-conjugated) anti- 
rabbit (A9169) and mouse (A4416) IgG (Sigma-Aldrich St. Louis, MO) was used to 
detect the primary antibody respectively. The chromogenic DAB substrate (Thermo, 
Rockford, IL) was used in color developing. 
Quantification of Recombinant Human Factor IX (rF9) and Recombinant Human 
Pro-peptide attached Factor IX (pro-rF9) in Transgenic Milk  
Western blot was performed as described before. Mononine, as calibrator, was loaded 
along with the transgenic milk samples (triplicated). The concentration mononine was 
determined by measuring the optical density at 280 nm in a 1 cm quartz cuvette and using 
an extinction coefficient, ε1% =13.4. The amount of tg-FIX was then calculated by using 
the standard curve created by the calibrators. The pictures of the blots were analyzed by 
using the Image J(31,32). 
Quantification of FIX by ELISA 
The procedure was modified from previous literature (33). Enzyme immunosorbent assay 
plates (Greiner Bio-One, Monroe, NC) were coated overnight at 4°C with 100 µL at 2 
µg/ml mouse anti-human factor IX IgG (Haematologic Technologies, Inc., Essex 
Junction, VT) per well in carbonate buffer. Factor IX samples at 100 µL/well including 
those for the standard curve (0.98-200 ng/mL) were incubated for 2 hours at 25°C. Then 
sheep anti-human factor IX IgG conjugated with horseradish peroxidase (HRP; Affinity 
Biologicals, Hamilton, Canada) (100 µL/well at 1 µg/ml in blocking buffer) was added 
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and incubated for 1 hour at 25 °C. After washing, 150 µL/well 1-step ABTS (Thermo, 
Rockford, IL) was added and color was allowed to develop up to 45 minutes and 
measuring absorbance at 405 nm. 
Quantitation of Total Factor IX Activity 
Total FIX activity was determined using the activated partial thromboplastin time (aPTT) 
assay (34). Briefly, 50µl each of PTT Automate 5 reagent (Diagnostica Stago, Inc., 
Parsippany, NJ, USA), factor IX deficient plasma (George King Bio-Medical, Overland 
Park, Kansas, USA), and a sample of interest were added to a cuvette and incubated at 
37 °C for 3 min. 50 µL of 25mM CaCl2 (Sigma) was then added and the clotting time 
was measured using the STart Hemostasis Analyzer (Diagnostica Stago, Inc., Parsippany, 
NJ). The normal human plasma (Diagnostica Stago, Inc., Parsippany, NJ) was used as the 
standard, assigning 1 unit of FIX clotting activity per milliliter of plasma. The 
concentration of purified tg-FIX was determined by measuring the optical density at 280 
nm in a 1 cm quartz cuvette and using an extinction coefficient, ε1% =13.4. 
NH2-terminal Sequencing of the Plasmin Cleavage Products of FIX 
Amino acid sequencing was performed at the University of Nebraska Medical Center, 
Protein Structure Core Facility. Protein samples were subjected to SDS-PAGE and 
transferred to PVDF as described above. The membrane was stained with Colloidal Blue 
and bands excised and subjected to Edman degradation using Applied Biosystems 
Procise protein sequencer, a Hitachi 8800 Amino Acid Analyzer and a Michrom MAGIC 
HPLC equipped with a Diode Array Detector. 
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RESULTS 
Capture Total TG-FIX Population in Transgenic Milk by FIX Select 
The camelid IgG anti-FIX based immunoaffinity column was used in capture whole tg-
FIX population in the transgenic milk. A sharp peak in the elution step followed the huge 
amount unbound flow through (FL) and tiny amount of wash (Fig.1A); the recovery of 
tg-FIX by using FIX select column was ~ 85% (Table 3). The  heparin affinity 
chromatography, widely used in purifying FIX from both plasma, mammalian cell culture 
and transgenic milk, required additional wash step to removed caseins and other 
impurities in milk; the quantity of these heparin binding impurities was larger than the tg-
FIX population and taking large amount of binding capacity of the column (Fig. 1B). By 
comparing the BCA results (total protein in sample) and FIX specific ELISA (tg-FIX in 
sample), FIX select eluate (EL) (batch112213) was about 95% tg-FIX (data not shown). 
The non-reduced SDS-PAGE showed FIX select EL was much purer (Fig. 1C, lane 2) 
than EL from heparin affinity chromatography (Fig. 1C). Large quantity of porcine 
plasmin was detected in the milk sample. No plasmin signal could be detected in the EL 
sample after the chromatography (Fig. 1E), which indicate the efficiency of FIX select in 
removing protease in the milk sample. The FIX select EL was then analyzed by the 
HPLC-SEC, it had only peak 1 compared to 3 peaks (larger peak 2 and 3) of high acidic 
tg-FIX (batch040813) (Fig. 1D). The FIX specific activity of the FIX select EL was 174 
± 10 U/mg (Avg. ± SD, n=3), looks “normal” compared to the 200 U/mg of pd-FIX. 
However, this activity was contributed mostly by the activated tg-FIX population (SEC 
pool 3, 2288 ± 204 U/mg) (Avg. ± SD, n=3) (Table 1) 
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Fig. 1. Comparison of FIX Purification by FIX Select and Heparin. A. Chromatograph of FIX 
select run of transgenic milk sample (K108). B. Chromatograph of Heparin Hyper D run of 
transgenic milk sample (k82, k89, k92 and k102 pool). FL: Flow through of the sample; W: Wash; 
EL: Elution; Strip: 2 M NaCl; EtOH: Ethanol. The blue line indicate the protein (OD280), the 
green line indicate the conductivity (mS) and the red line indicate the pH. C. Non-reduced SDS-
PAGE of total FIX population captured by FIX select or Heperin Hyper D. Lane 1: Clarified milk; 
Lane 2: Eluate from FIX select run; Lane 3: Eluate from Heparin Hyper D run. The arrow 
indicates the FIX in eluate of Heparin Hyper D. D. Comparison of SEC profiles of FIX select EL 
(batch112213) and CHT EL 2 (batch040813). E. Non-reduced Western blot detecting porcine 
plasmin in purified  tg-FIX sample and transgenic milk sample. Lane 1, tg-FIX111413 (FIX 
select EL), 20 µg; lane 2, tg-FIX040813 (CHT EL2), 10 µg; lane 3, human plasmin (83 kDa), 1 
µg; lane 4, human plasminogen (88 kDa), 1 µg; lane 5-9, transgenic milk K75, K101, R175&179, 
R180 and R1014 lactation pool, diluted 1:1 (v/v) and skimmed, 10 µL (about 10 µg tg-FIX). 
 
Isolation of High Acidic Tg-FIX from FIX Select Eluate 
Q sepharose fast flow column was used in isolating high acidic, active, tg-FIX population 
and the methods were adapted from gradient (27) to step wash (Fig. 2A). The Q EL 
(batch 091713) had 4 times more FIX specific activity than the FIX select EL 
(batch112213), and an additional lower band (45 kDa) than the wash fraction (Fig. 2D, 
lane 3-4). We noticed the increasing in activity was from both the fraction of active tg-
FIX, SEC pool 2, and activated tg-FIX (tg-FIXa), SEC pool 3 (Table 1).  
The Ceramic Hydroxyapatite (CHT) chromatography was performed after Q to further 
enrich the high acidic tg-FIX. The high acidic tg-FIX subpopulation was enriched in 
latter 80% EL (EL 2), whose peak 1 on the HPLC-SEC was less than CHT EL 1 (Fig. 2B, 
2C). Like the Q EL, CHT EL 2 had more 45 kDa band on the non-reduced gel (as shown 
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in the Q EL) (Fig. 2D, lane 5 and 6).  SEC pools of CHT ELs loaded on reduced SDS-
PAGE was analyzed by N-terminal amino acids sequencing, majority of the pool 3, 
which only shown in EL 2, was tg-FIXa (the 28 kDa band showed a.a. sequence of 
VVGGE, indicating the heavy chain of tg-FIXa), while no tg-FIXa was detected in CHT 
EL 1 (Fig. 2E), This was also confirmed by the activity assay (Table 1 and 2). 
Batch Samples 
Mass 
Percentage % 
Specific Activity (U/mg) 
112213 
FIX Select 
Eluate 
100 174 ± 10 
SEC Pool 1 55 1 ± 0 
SEC Pool 2 43 9 ± 1 
SEC Pool 3 1 2288 ± 204 
91713 
Q Eluate 100 714 ± 7 
SEC Pool 1 21 9  ± 1 
SEC Pool 2 43 107  ± 7 
SEC Pool 3 36 2755 ± 182 
40813 
CHT Eluate 100 2351 ± 335 
SEC Pool 1 16 No Activity 
SEC Pool 2 41 165 ± 9 
SEC Pool 3 43 4284 ± 728 
42313 
CHT Eluate 100 1471 ± 147 
SEC Pool 1 18 No Activity 
SEC Pool 2 48 138 ± 8 
SEC Pool 3 34 3753 ± 278 
Table 1. Comparison of FIX Purification Samples by using Analytical HPLC-SEC. 
About 700 µg FIX eluate sample of each batch (purified by using different procedures) 
was loaded on HPLC-SEC and the fractions were pooled (SEC pool 1, 18-19.5 min; SEC 
pool 2, 20-22 min; and SEC pool 3, 22.5-27 min) and calculated FIX specific activity. All 
above batches were purified from the transgenic milk (K108). The mass percentage was 
calculated based on amount of FIX in each fraction. The specific activity of control 
plasma derived FIX was 211 ± 9 U/mg (Avg. ± SD, n=3). 
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Fig. 2. Isolation of High Acidic FIX by Using Ion-exchange Chromatography. A. Q 
sepharose FF run. B. CHT run. Flow through (FT), wash (W) and eluate (EL) were 
labeled. The blue line indicate the protein (OD280), the green line indicate the conductivity (mS). 
C. Comparison of SEC profile of CHT EL 1 and 2 (batch031313). D. Non-reduced SDS-
PAGE of FIX purified from Q and CHT (batch040813). Lane 1: FIX select EL; Lane 2: Q 
FT ; Lane 3: Q wash; Lane 4: Q EL; Lane 5: CHT EL 1; Lane 6: CHT EL 2. E. Reduced 
SDS-PAGE of FIX samples (Batch031313). Lane 1: CHT EL 1; Lane 2: CHT EL 1 SEC 
pool 1; Lane 3: CHT EL 1 SEC pool 2; Lane 4: CHT EL 2; Lane 5: CHT EL 2 SEC pool 
2; Lane 6: CHT EL 2 SEC pool 3. The 28 kDa band of each lane was sequenced and the 
N-terminal first 5 amino acid sequence listed. 
 
Separate Active Tg-FIX from High Acidic Tg-FIX population by High 
Performance/Pressure Liquid Chromatography-Size Exclusion Chromatography 
(HPLC-SEC) 
Although the FIX had been purified into a highly acidic tg-FIX subpopulation, the FIX 
material only contained ~40% active tg-FIX analyzed by HPLC-SEC. The CHT EL 2 
(batch040813) had about 10% non-active tg-FIX species and the other ~40% was mixture 
of tg-FIXa and degraded tg-FIX (mostly tg-FIXɤ) (Table 1). To scale up the separation of 
active tg-FIX from no-active and tg-FIXa/degraded tg-FIX, TSK gel G3000SW with 21.5 
mm ID x 60 cm L, 13 µm (particle size) at higher throughputs was applied in purification 
procedure.  We noticed resolution in separation of peak 2 and 3 was better in using the 
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processing HPLC-SEC (Fig.3). However, with 10-folds higher load on the HPLC-SEC, 
approximately 30% of total loaded tg-FIX came out before the regular 3 peaks, which 
was not present in analytical runs and was considered as the aggregation of tg-FIX 
sample. 
CHT Eluate 
(Mass Percentage) 
SEC Pool 
Specific Activity (U/mg) (Mass Percentage) 
 
1 2 3 
1 (8%) 11 ±1 (31.6%) 122 ±7 (68.4 %) N/A 
2 (73%) 25 ±3 (18 %) 155 ±13 (46 %) 3203 ±890 (37 %) 
Table 2. Comparison of CHT eluate 1 and 2 SEC pools (Batch031313) (Avg. ± SD, n=3). 
 
Fig. 3. Processing HPLC-SEC Profile of CHT EL 2 (batch031313). 10 mg FIX CHT 
EL 2 (~ 2mg/ml) was loaded on the TSK gel G3000SW (21.5 mm ID x 60 cm L) with 
running buffer (20 mM Tris, 200 mM NaCl, 10 mM CaCl2, pH 7.0). The Flow rate was 3 
ml/ min. The run was 90 min. All peaks came out before 60 min. Fractions were pooled 
as indicated on the figure. 
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Inefficiency in Separating Tg-proFIX from Active Tg-FIX 
We previously reported the inefficiency in processing of pro-peptide of tg-proFIX (pro-
peptide attached tg-FIX) by endogenous porcine furin in mammary gland [paper in draft].  
 
 
Fig. 4. Reduced SDS-PAGE and Western blots of FIX purified by HPLC-SEC. A. 
Reduced SDS-PAGE; B. Reduced Western blot developed by using antibody anti-total 
FIX; C. Reduced Western blot developed by using antibody anti-proFIX. Lane 1: High 
acidic FIX (4 µg, Q Sepharose eluate, batch091713); Lane 2: SEC pool 1 of high acidic 
FIX (2 µg, non-active FIX); Lane 3: SEC pool 2 of high acidic FIX (2 µg, active FIX); 
Lane 4: SEC pool 3 of high acidic FIX (1 µg, activated FIX or FIXɤ) (SEC pool 1, 18-
19.5 min; SEC pool 2, 20-22 min; and SEC pool 3, 22.5-27 min). The concentration of 
each FIX sample was measured by optical density with wavelength = 280 nm, ε
1%
 = 13.4. 
D. Western blot of  removal of propeptide of  FIX by furin co-expressed in the transgenic 
milk. Lane 1: Furin co-expressed FIX milk (0.8 µL, R175); Lane 2: FIX depleted furin 
co-expressed FIX milk (0.8 µL); Lane 3: FIX milk (0.8 µL, K96); Lane 4: Sample of 
furin co-expressed FIX milk incubated with FIX milk, 1:2 (v/v) at 4 C for 1.5 hour; Lane 
5: Sample of furin co-expressed FIX milk incubated with FIX milk, 1:4 (v/v) at 4 C for 
1.5 hour. All samples were whole milk without EDTA or protease inhibitor treatment.  
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We noticed the ion-exchange chromatography could not separate the non-active tg-
proFIX from the active tg-FIX. The high acidic tg-FIX (batch 091713, without pro-
peptide cleavage) contained a large portion of tg-proFIX (Fig. 4, lane 1). HPLC-SEC 
failed in separating tg-proFIX, 2 kDa difference, from FIX zymogen. All three SEC pools 
contained tg-proFIX (Fig. 4, lane 2-4), which decreased the activity of final FIX samples 
(batch 091713) (Table 1). To eliminate tg-proFIX and recover the activity by converting 
inactive tg-proFIX to active zymogen, the pro-peptide needs to be processed before all 
purification steps. Tg-proFIX was converted into tg-FIX after incubated with tg-furin in a 
lab scale expriment (Fig. 4D, lane 4 and 5). For large preparation, the FIX milk (K108) 
was treated with the tg-furin-FIX milk (R185) at 1:4 ratio at room temperature for 2 
hours before the FIX select step. No tg-proFIX was detected in the final produce (data not 
shown), and the FIX specific activity of tg-FIX sample (batch040813 SEC pool 2) was 
increased (Table 1). 
Minimize the tg-FIX Degradation during the Purification 
We previous reported that the major protease in transgenic swine milk, plasmin, degrades 
the tg-FIX [paper in draft]. In addition, some other protease, such as trypsin, might be 
also involved in the proteolysis of tg-FIX in transgenic milk (35).  The ε-aminocaporic 
acid (EACA), which is the specific inhibitor of plasmin, and benzamidine, inhibiting 
trypsin, was used to prevent the degradation of tg-FIX in milk. SEC profile of batch 
040813, which was not treated PIs, has larger peak 3 (43%), than the batch 042313 (34%), 
which was treated PIs (Fig. 5, Table 1), although both batches were used the same 
transgenic milk sample. The activity assay showed batch 040813 has more tg-FIXa 
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(Table 1).  So, introducing PIs helped decreasing the activation/degradation of tg-FIX in 
the milk sample. 
Fig. 5. Comparison the SEC profile of Purified FIX Sample with or without treated 
by protease inhibitors. The upper one was not treated by PIs (batch 040813). The lower 
one was treated by PIs (batch 042313). Both batches were from same milk and using the 
same purification procedures. 
 
 
CONCLUSION 
The mammary gland of transgenic swine has the advantages, including the high cell 
density in the gland tissue, the high volume of milk produced per swine, the high 
recombinant protein yield and its capability to perform certain PTMs for recombinant 
human coagulation proteins, making it a promising bioreactor for producing FIX 
economically. Biologically active recombinant human coagulation factors have been 
successfully produced in pig milk and reported by several studies, such as human F8 (36), 
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protein C (37) , VWF(38) and F9 (27,39). Additionally, the capital investment is 
substantially less than the traditional steel bioreactor for both mammalian cells and 
bacteria. However, the complexity of the milk, such as the large quantity of the native 
proteins and multiple phase nature, make it more of a challenge for downstream 
processing than current mammalian and bacteria system.  
Purification Step 
Batch031313 
FIX in Eluate (mg) 
(Overall Yield %) 
Batch040813 
FIX in Eluate (mg) 
(Overall Yield %) 
Clarified Milk 1400 (100) 1400 (100) 
FIX Select  1171 (84) 1180 (84) 
Q Sepharose  136 (10) 169 (12) 
CHT 88 (6) 92 (7) 
SEC 32 (2) 38 (3) 
Table 3. Purification Table of Active FIX from Transgenic milk. Both batches were 
purified from the same pig milk, batch 031313 was using the lactation day 16-19 pool, 
and batch040813 was used the lactation day 5-14 pool. 
 
The new camelid IgG anti-FIX immuno-affinity chromatography, more efficient than the 
traditional heparin affinity column, captured whole FIX population with about 84% yield 
and close to 100% purity (Table 3). The efficiency in purifying tg-FIX from impurities is 
also important in decreasing the proteolysis of tg-FIX by proteases, e.g. porcine plasmin, 
in the milk. In addition, no acidic pH was needed in elution steps that are required by 
traditional immunoaffinity chromatography. The ion-exchange chromatography, Q 
sepharose and Ceramic Hydroxyapatite columns were used to isolated high acidic 
(activity) tg-FIX. These two chromatography enriched active tg-FIX subpopulation, 
resulting in a specific activity increased more than 10 fold (Table 1). Finally, the property 
of ɤ-carboxylglutamic acid residue conducting a size compaction in the presence of 
93 
 
calcium ions was utilized to further separated active tg-FIX subpopulation from the non-
active tg-FIX subpopulations by HPLC-SEC; and the activated/degraded tg-FIX 
subpopulation was also eliminated caused by the molecular weight difference.  
We noticed the amount of activated and degraded tg-FIX decreased about 9% (mass) by 
adding the protease inhibitors. By co-expressing tg-furin, which processes excessive pro-
peptide in transgenic milk [paper in draft], no extra cleavage step needed and EDTA and 
PIs can be added right after milking. This will further improve the yield of active tg-FIX 
by decreasing activation and degradation of tg-FIX.  
The overall yield of active tg-FIX was approximated 3% of whole tg-FIX population in 
the transgenic swine milk by using the purification protocol (Table 3). The final product, 
active tg-FIX, had about 200 U/mg FIX specific activity without any detected activated 
tg-FIX (tg-FIXa). Assuming average tg-FIX expression rate in pig was 2.5 mg/ml, and 
milk production was 400 liters per pig and per year, approximately 40 pigs could produce 
enough FIX concentrates for US consumption (250 million units) and 160 pigs was 
enough for the worldwide (1 billion units). We are now working on the project of 
introducing the vitamin K 2,3-epoxide reductase enzyme (VORK), which produces the 
cofactor for ɤ-carboxylase, gene and co-expressing with tg-FIX to accelerate the 
formation of ɤ-carboxylglutamate (Gla) that is relative pro-coagulant activity(40). The 
active tg-FIX subpopulation could be further increased. 
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CHAPTER 5 
SUMMARY AND FUTURE WORK 
SUMMARY 
The success in expressing recombinant human FIX (tg-FIX) with approximately 2-3 g/L 
and 10-20% bio-active in the milk (1) makes this mammary gland of transgenic pig a 
promising bioreactor in producing recombinant human FIX with full pro-coagulate 
activity. The goal of this project was to increase the yield of the bio-active tg-FIX, and 
this was fulfilled by the following specific aims: 
Specific Aim#1: Characterize the tg-FIX and its degraded species in the milk sample. 
And investigate the predominant milk-borne protease, plasmin, in degrading the tg-FIX. 
Specific Aim#2: Bioengineer pig mammary gland by introducing truncated human furin 
gene co-expressing with tg-FIX. Characterize the recombinant truncated human furin (r-
furin) in processing the excessive pro-peptide and convert non-active tg-proFIX to active 
tg-FIX both in vivo and in vitro.  
Specific Aim#3: Establish scaled-up purification protocol, using the more efficient, 
immune-affinity chromatography FIX select column to capture whole tg-FIX population 
from transgenic milk; then enrich high acidic tg-FIX by anion exchange chromatography; 
finally separate the active tg-FIX subpopulation from the inactive and activated tg-FIX 
subpopulation.  
We noticed about 50% of the high extent ɤ-carboxylated tg-FIX was activated or 
degraded in the purified high acidic tg-FIX. By investigating the degraded species, 
plasmin, which is the predominant protease in milk, was involved the degrading and 
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facilitate activating the tg-FIX in the milk. The extent of degradation/activation of tg-FIX 
could be decreased by introducing the protease inhibitors, by introducing the ε-
aminocaporic acid (EACA), which is the specific inhibitor of plasmin, and benzamidine 
during the storage of milk. The percentage of degraded/activated tg-FIX dropped from 43% 
to 34%. However the degradation and activation before collecting milk could not be 
reversed. We noticed the tg-FIX having high extent Gla, which conducted the 
conformation change in Gla domain in presence of calcium ion, was prevented light chain 
being cleaved by plasmin. However, cleaved at C-terminal of catalytic domain and 
deactivated the tg-FIX happened not dependent on its Gla content and in presence of 
calcium ion or in chelated environment.  The plasmin also performed cleavage at Arg
145
, 
making FIXα (intermediate of activated FIX), facilitated the activation of tg-FIX, which 
only needed one more cleavage at Arg
180
. In order to increase the yield of active tg-FIX, 
the action of the protease in the milk need to minimize.  
In the tg-FIX expressed only transgenic pig, we noticed approximately 10-30% pro-
peptide attached tg-FIX, which was not processed by endogenous porcine furin in the 
mammary epithelium during the tg-FIX synthesis. And this unprocessed pro-tgFIX, 
which interferes conformational changes in Gla domain causing no pro-coagulation 
activity, could not be separated by current purification methods. This causes the 
decreasing in FIX specific activity of the purified tg-FIX sample; in addition, the pro-
tgFIX, which has high extent Gla, could be waste if we left it unprocessed. By 
introducing the truncated human furin cDNA and co-expressing with the tg-FIX, this tg-
furin, with furin specific activity, helped the endogenous porcine furin in processing 
over-expressed nascent tg-FIX. In addition, without the transmembrane domain, this tg-
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furin secreted into the milk, and approved to process pro-peptide in vitro also. No pro-
tgFIX was detected with co-expressing this tg-furin. More important, no evidence 
showed this this co-expressed tg-furin decreasing the percentage of the active tg-FIX, 
which indicated the over-expressed tg-furin did not interfere the formation of gamma-
carboxylation in tg-FIX in ER.  
The scaled-up purification protocol was established with modifying the previous lab-
scale one. By introducing the new camelid IgG based immunoaffinity chromatography, 
the capture of whole tg-FIX population is more efficient than the current heparin based 
affinity chromatography. The anion exchange chromatography further enriched the high 
acidic tg-FIX subpopulation, which is highly related to its extent of Gla. And the HPLC-
SEC not only separated the active tg-FIX from non-active (low extent of Gla) tg-FIX, and 
also the activated, also high extent Gla, tg-FIX by their size difference in presence of 
calcium ion. The final tg-FIX showed smilar specific activity to the plasma-derived and 
recombinant (CHO) FIX.  
FUTURE WORK 
Approximately half of the high acidic tg-FIX subpopulation were degraded or activated 
in the milk sample and during the processing. The degradation and activation after tg-FIX 
secreting into the milk could not be reversed. The plasmin specific inhibitor, α2-
antiplasmin (A2AP), could be the candidate in inhibiting the plasmin activity in the 
milk(2). The efficiency of co-expressing this serine protease inhibitor with the tg-FIX 
needs to be investigated. Also, the precaution needs to be taken, since both tg-FIX and 
furin are serine protease, the co-expressed A2AP might inhibit their activity. In addition, 
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since the A2AP involves in inhibiting plasmin activity in blood, the current purification 
protocol and the final purified tg-FIX need to be investigated to remove all A2AP. 
The current expression level of recombinant human FIX in milk of transgenic pig is about 
2-3 g/L, however, only 10-20% high acidic/carboxylated FIX population could be 
enhanced. It is believed that incomplete-carboxylation occurs when an excess of newly 
synthesized precursors of vitamin K-dependent proteins appears in the ER and exceeds 
the capacity of the cell’s-carboxylation system to fully modify all of the precursors (3,4). 
The under-carboxylated FIX is less active, prone to be degraded, and cleared more 
rapidly from the bloodstream than fully carboxylated FIX (5). The reduced form of 
vitamin K, vitamin K hydroquinone (KH2), is the cofactor as carboxylase in the reaction 
of ɤ-carboxylation(6). This KH2 is recycle between its oxidized form by the enzyme, 
vitamin K epoxide reductase (VKOR)(6).  So, this VKOR maintains the level of the KH2 
and also accelerate the reaction of carboxylase(7,8), and the truncated recombinant 
human VKOR, an 18-kDa ER membrane protein VKORC1(9), was expressed and proven 
in increasing production of functional FIX in the CHO cells(10). With the success in 
bioengineering of the mammary gland of pig in processing excessive pro-peptide of FIX 
by co-expressing the truncated recombinant human furin, introducing this VKORC1 
could increase the yield of fully carboxylated FIX. 
At the meanwhile, the in vivo effects of our recombinant human FIX, expressed and 
purified as in the previous study, should be investigated in pharmacokinetics by using 
animal models. The wild type mice (as control), hemophilia mice, including R333Q 
mice(11) and FIX knockout (FIXKO) mice (12), and hemophilia dog(13) will be 
administrated intravenously using purified active tg-FIX in multiple doses and the FIX 
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antigen and activity level will be monitored by the ELISA and aPTT, respectively, at 
multiple time points after administration. Oral administration of coagulation therapy will 
obviate the invasiveness, discomfort, potential for opportunistic infection, and 
complications of storage and supplies that accompany with current intravenous 
administration. With the progress in producing recombinant human FIX economically in 
mammary gland of transgenic pig, the cost of the FIX concentrates would drop and make 
this oral administration affordable. The safety and efficiency of oral administration of this 
recombinant human FIX should also be investigated by using the animal models that 
were used in intravenous administration. 
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